[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 801
1. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Tomlinson IP, Taylor M, Greaves M, Houlston RS: Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet; 2009 Sep;41(9):1006-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia.
  • To identify risk variants for childhood acute lymphoblastic leukemia (ALL), we conducted a genome-wide association study of two case-control series, analyzing the genotypes with respect to 291,423 tagging SNPs in a total of 907 ALL cases and 2,398 controls.
  • The 10q21.2 (ARID5B) risk association appears to be selective for the subset of B-cell precursor ALL with hyperdiploidy.
  • These data show that common low-penetrance susceptibility alleles contribute to the risk of developing childhood ALL and provide new insight into disease causation of this specific hematological cancer.
  • Notably, all three risk variants map to genes involved in transcriptional regulation and differentiation of B-cell progenitors.
  • [MeSH-major] Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 7. Genetic Predisposition to Disease. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology


2. von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, Zemanova Z, Stary J, Bourquin JP, Haas OA, Dworzak MN, Creutzig U: Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol; 2010 Jun 1;28(16):2682-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
  • PURPOSE: Because cytogenetic data are essential for risk stratification of childhood acute myeloid leukemia (AML), the impact of chromosomal aberrations is crucial.
  • CONCLUSION: Because the prognostic value of rare recurrent chromosomal aberrations still has to be elucidated, these data will contribute to future risk stratification for the treatment of pediatric AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chromosome Aberrations. Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Combined Modality Therapy. Confidence Intervals. Cytarabine / administration & dosage. Cytogenetic Analysis. Disease-Free Survival. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Idarubicin / administration & dosage. In Situ Hybridization, Fluorescence. Male. Probability. Proportional Hazards Models. Radiotherapy, Adjuvant. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Severity of Illness Index. Statistics, Nonparametric. Stem Cell Transplantation. Survival Analysis. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20439630.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; ZRP63D75JW / Idarubicin; ICE protocol 4
  •  go-up   go-down


3. Lowe EJ, Sposto R, Perkins SL, Gross TG, Finlay J, Zwick D, Abromowitch M, Children's Cancer Group Study 5941: Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941. Pediatr Blood Cancer; 2009 Mar;52(3):335-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941.
  • BACKGROUND: Anaplastic large cell lymphoma (ALCL) is characterized by advanced disease at presentation (70-80% of pediatric cases) and accounts for 10-15% of all childhood lymphomas.
  • Treatment strategies for pediatric ALCL vary from short pulse B-NHL chemotherapy to prolonged leukemia like therapy.
  • METHODS: CCG-5941 used a compressed aggressive multiagent T-cell lineage chemotherapy regimen consisting of a 3-week induction therapy (vincristine, prednisone, cyclophosphamide, daunomycin, asparaginase) followed by a 3-week consolidation period (vincristine, prednisone, etoposide, 6-thioguanine, cytarabine, asparaginase, methotrexate) followed by six courses of maintenance chemotherapy at 7-week intervals (cyclophosphamide, 6-thioguanine, vincristine, prednisone, doxorubicin, asparaginase, methotrexate etoposide, cytarabine).


Advertisement
4. Suzuki N, Yumura-Yagi K, Yoshida M, Hara J, Nishimura S, Kudoh T, Tawa A, Usami I, Tanizawa A, Hori H, Ito Y, Miyaji R, Oda M, Kato K, Hamamoto K, Osugi Y, Hashii Y, Nakahata T, Horibe K, Japan Association of Childhood Leukemia Study (JACLS): Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia study (JACLS) ALL F-protocol. Pediatr Blood Cancer; 2010 Jan;54(1):71-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia study (JACLS) ALL F-protocol.
  • BACKGROUND: Children with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission (CR) after induction therapy (induction failure: IF) have a poor prognosis; however, there have been few prospective studies in patients with IF.
  • Twenty-three of these patients entered the F-protocol study, which mainly consisted of acute-myeloid-leukemia-oriented chemotherapy followed by scheduled hematopoietic cell transplantation (HCT).
  • CONCLUSION: Acute-myeloid-leukemia-oriented chemotherapy followed by scheduled HCT is a promising treatment strategy for non-Ph(+) ALL patients with IF.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


5. Steiner M, Attarbaschi A, König M, Gadner H, Haas OA, Mann G: Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome. Pediatr Hematol Oncol; 2005 Jan-Feb;22(1):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome.
  • Constitutional trisomy 21 is the most prominent predisposing factor to childhood leukemia, whereas the t(12;21)(p13;q22) with its molecular genetic counterpart, the TEL/AML1 fusion gene, is the most common acquired chromosomal rearrangement in childhood B-cell precursor (BCP) acute lymphoblastic leukemia (ALL).
  • Accordingly, they were able to analyze 8 of 10 individuals with DS and a BCP ALL, including 2 who suffered from a TEL/AML1+ leukemia.
  • Based on this observation we concluded that individuals with a constitutional trisomy 21 may have the similar likelihood to develop a TEL/AML1+ leukemia as BCP ALL patients without this specific predisposingfactor.
  • [MeSH-major] Down Syndrome / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedIn] Pediatr Hematol Oncol. 2005 Apr-May;22(3):229-34 [16020107.001]
  • (PMID = 15770827.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


6. Wu QW, Cai PC, Wang L, Li YR, Kong LL, Hu LH: Family-based association study of Tim-1 and Tim-3 gene polymorphisms with childhood asthma in Chinese trios. Int Arch Allergy Immunol; 2009;150(3):252-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family-based association study of Tim-1 and Tim-3 gene polymorphisms with childhood asthma in Chinese trios.
  • T cell immunoglobulin domain and mucin domain (Tim) genes are located in chromosome 5q31-33, a region repeatedly linked to asthma or asthma-related phenotypes in several populations.
  • Two members of Tim families, Tim-1 and Tim-3, which are expressed on T cell surface and potentially involved in T cell proliferation and differentiation, are good candidate genes for asthma.

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19494522.001).
  • [ISSN] 1423-0097
  • [Journal-full-title] International archives of allergy and immunology
  • [ISO-abbreviation] Int. Arch. Allergy Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / HAVCR1 protein, human; 0 / HAVCR2 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Receptors, Virus
  •  go-up   go-down


7. Prasad RB, Hosking FJ, Vijayakrishnan J, Papaemmanuil E, Koehler R, Greaves M, Sheridan E, Gast A, Kinsey SE, Lightfoot T, Roman E, Taylor M, Pritchard-Jones K, Stanulla M, Schrappe M, Bartram CR, Houlston RS, Kumar R, Hemminki K: Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood; 2010 Mar 4;115(9):1765-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood.
  • Recent genome-wide association data have implicated genetic variation at 7p12.2 (IKZF1), 10q21.2 (ARIDB5), and 14q11.2 (CEBPE) in the etiology of B-cell childhood acute lymphoblastic leukemia (ALL).
  • To verify and further examine the relationship between these variants and ALL risk, we genotyped 1384 cases of precursor B-cell childhood ALL and 1877 controls from Germany and the United Kingdom.
  • [MeSH-major] Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 7 / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics


8. Ashfaq K, Yahaya I, Hyde C, Andronis L, Barton P, Bayliss S, Chen YF: Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technol Assess; 2010 Dec;14(54):iii-iv, ix-xi, 1-141
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review.
  • BACKGROUND: Acute leukaemia is a group of rapidly progressing cancers of bone marrow and blood classified as either acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL).
  • Haemopoietic stem cell transplantation (SCT) has developed as an adjunct to or replacement for conventional chemotherapy with the aim of improving survival and quality of life.
  • OBJECTIVES: A systematic overview of the best available evidence on the clinical effectiveness and cost-effectiveness of SCT in the treatment of acute leukaemia.
  • Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.
  • CONCLUSIONS: Bearing in mind the limitations, existing evidence suggests that sibling donor allogeneic SCT may be more effective than chemotherapy in adult AML (except in good-risk patients) in CR1, childhood AML in CR1 and adult ALL in CR1, and that autologous SCT is equal to or less effective than chemotherapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery


9. Hamouda F, El-Sissy AH, Radwan AK, Hussein H, Gadallah FH, Al-Sharkawy N, Sedhom E, Ebeid E, Salem SI: Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia; experience at the National Cancer Institute, Cairo University, Egypt. J Egypt Natl Canc Inst; 2007 Jun;19(2):87-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia; experience at the National Cancer Institute, Cairo University, Egypt.
  • The frequency of pseudodiploidy was 36.8% in CALLA positive early pre B, 30.7% in pre B cases, 71.4% in T cell cases and 100% in mature B cell cases.
  • Sixteen percent of the studied cases showed T cell phenotype, 71.4% of them showed pseudodiploid karyotype, all of them had high risk features.
  • [MeSH-major] Antigens, Neoplasm / analysis. Immunophenotyping / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology


10. Baldo M, Bhogal B, Groves RW, Powell J, Wojnarowska F: Childhood vulval lichen sclerosus: autoimmunity to the basement membrane zone protein BP180 and its relationship to autoimmunity. Clin Exp Dermatol; 2010 Jul;35(5):543-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood vulval lichen sclerosus: autoimmunity to the basement membrane zone protein BP180 and its relationship to autoimmunity.
  • In adult women, there are antibody and T-cell responses to proteins in the basement membrane zone (BMZ).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20456392.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Non-Fibrillar Collagens; 0 / collagen type XVII
  •  go-up   go-down


11. Skoczeń S, Balwierz W, Moryl-Bujakowska A, Pawińska K, Luszczyńska A, Balcerska A, Płoszyńska A, Chybicka A, Dobaczewski G, Juszczak K, Wachowiak J, Derwich K, Kowalczyk J, Wiśniewska-Slusarz H, Matysiak M, Krauze A, Pawelec K, Sońta-Jakimczyk D, Tomaszewska R, Wysocki M, Styczyńskii J, Swiatkiewicz V, Polish Pediatric Leukemia/Lymphoma Study Group: [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group]. Przegl Lek; 2006;63(1):11-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
  • From 1981 to 1986, children with acute lymphoblastic leukemia (ALL) and initial WBC above 50,000/mm3, achieved significantly worse treatment results than children with lower WBC: over 6-year disease-free survival were respectively 33% and 60%.
  • In attempt to improve treatment results in children with hyperleucocytosis, modified American protocols called: New York (1987), New York I (1997), and New York II (1999) were introduced consecutively in the centers of Polish Pediatric Leukemia/ Lymphoma Study Group.
  • There is strong necessity of unification of risk group qualification criteria in childhood ALL in term of comparable estimation treatment results achieved in different centers all over the world.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16892892.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Poland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; EC 3.5.1.1 / Asparaginase; FTK8U1GZNX / Thioguanine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; New York protocol
  •  go-up   go-down


12. Londono P, Komura A, Hara N, Zipris D: Brief dexamethasone treatment during acute infection prevents virus-induced autoimmune diabetes. Clin Immunol; 2010 Jun;135(3):401-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brief dexamethasone treatment during acute infection prevents virus-induced autoimmune diabetes.
  • [MeSH-minor] Animals. Antibodies, Viral / blood. Antibodies, Viral / immunology. Cell Separation. Flow Cytometry. Immunity, Innate / immunology. Parvoviridae Infections / complications. Parvovirus. Rats. Rats, Inbred Lew. Reverse Transcriptase Polymerase Chain Reaction. T-Lymphocyte Subsets / drug effects. T-Lymphocyte Subsets / immunology. T-Lymphocytes / drug effects. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Elsevier Inc. All rights reserved.
  • (PMID = 20167539.001).
  • [ISSN] 1521-7035
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK57516
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Viral; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


13. Kikuchi A, Mori T, Fujimoto J, Kumagai M, Sunami S, Okimoto Y, Tsuchida M: Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children's Cancer Study Group NHL B9604 protocol. Leuk Lymphoma; 2008 Apr;49(4):757-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children's Cancer Study Group NHL B9604 protocol.
  • From June 1996 to January 2001, 91 patients with B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia up to 18 years of age were enrolled in Tokyo Children's Cancer Study Group (TCCSG) NHL B9604 protocol study.
  • The TCCSG NHL B9604 protocol achieved an excellent treatment outcome especially in patients with the most advanced disease (Group D: high BM blast cell burden and/or central nervous system involvement).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, B-Cell / drug therapy


14. Salsano ME, Graziano L, Luongo I, Pilla P, Giordano M, Lama G: Atopy in childhood idiopathic nephrotic syndrome. Acta Paediatr; 2007 Apr;96(4):561-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atopy in childhood idiopathic nephrotic syndrome.
  • AIM: Aim of the study was to evaluate the immunoallergic pattern and their modulating serum cytokines in children with primary manifestation of nephrotic syndrome, in order to analyse the correlation with disease activity and the outcome of childhood NS.
  • In all were measured serum: T cell-subset, cytokines by Th-1, Th-2, total IgE levels and specific IgE antibodies.
  • Therefore, specific IgE antibodies were not related to disease activity, suggesting that IgE production might be co-incident in childhood NS.

  • MedlinePlus Health Information. consumer health - Allergy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17326761.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Cytokines; 37341-29-0 / Immunoglobulin E; AYI8EX34EU / Creatinine
  •  go-up   go-down


15. Kormann MS, Depner M, Hartl D, Klopp N, Illig T, Adamski J, Vogelberg C, Weiland SK, von Mutius E, Kabesch M: Toll-like receptor heterodimer variants protect from childhood asthma. J Allergy Clin Immunol; 2008 Jul;122(1):86-92, 92.e1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toll-like receptor heterodimer variants protect from childhood asthma.
  • T-cell cytokine production was evaluated by means of ELISA after stimulation of the respective TLRs with specific ligands.

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18547625.001).
  • [ISSN] 1097-6825
  • [Journal-full-title] The Journal of allergy and clinical immunology
  • [ISO-abbreviation] J. Allergy Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / TLR6 protein, human; 0 / Toll-Like Receptor 1; 0 / Toll-Like Receptor 6; 0 / Toll-Like Receptors
  •  go-up   go-down


16. Adam de Beaumais T, Dervieux T, Fakhoury M, Medard Y, Azougagh S, Zhang D, Yakouben K, Jacqz-Aigrain E: The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol; 2010 Sep;66(4):653-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
  • PURPOSE: Low-dose methotrexate (MTX) therapy is the cornerstone treatment of acute lymphoblastic leukemia (ALL) and may enhance the activation of 6-mercaptopurine (6-MP) to 6-thioguanine nucleotides (6-TGN).
  • [MeSH-major] 6-Mercaptopurine / pharmacokinetics. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / pharmacokinetics. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033410.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine; FTK8U1GZNX / Thioguanine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


17. Ariffin H, Chen SP, Kwok CS, Quah TC, Lin HP, Yeoh AE: Ethnic differences in the frequency of subtypes of childhood acute lymphoblastic leukemia: results of the Malaysia-Singapore Leukemia Study Group. J Pediatr Hematol Oncol; 2007 Jan;29(1):27-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnic differences in the frequency of subtypes of childhood acute lymphoblastic leukemia: results of the Malaysia-Singapore Leukemia Study Group.
  • Childhood acute lymphoblastic leukemia (ALL) is clinically heterogeneous with prognostically and biologically distinct subtypes.
  • Although racial differences in frequency of different types of childhood ALL have been reported, many are confounded by selected or limited population samples.
  • The Malaysia-Singapore (MA-SPORE) Leukemia Study Group provided a unique platform for the study of the frequency of major subgroups of childhood ALL in a large cohort of unselected multiethnic Asian children.
  • Our study suggests that there are indeed significant and important racial differences in the frequency of subtypes of childhood ALL.
  • Comprehensive subgrouping of childhood ALL may reveal interesting population frequency differences of the various subtypes, their risk factors and hopefully, its etiology.
  • [MeSH-major] Asian Continental Ancestry Group. Chromosome Aberrations. Precursor Cell Lymphoblastic Leukemia-Lymphoma / ethnology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2007 Aug;29(8):585 [17762503.001]
  • (PMID = 17230064.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


18. Paulsson K, Mörse H, Fioretos T, Behrendtz M, Strömbeck B, Johansson B: Evidence for a single-step mechanism in the origin of hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer; 2005 Oct;44(2):113-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for a single-step mechanism in the origin of hyperdiploid childhood acute lymphoblastic leukemia.
  • High hyperdiploidy (>50 chromosomes) in childhood acute lymphoblastic leukemia (ALL) is characterized by nonrandom multiple trisomies and tetrasomies involving in particular chromosomes X, 4, 6, 8, 10, 14, 17, 18, and 21.
  • This characteristic karyotypic pattern, the most common in pediatric ALL, may arise via a tetraploid state with subsequent loss of chromosomes, by sequential gains of chromosomes in consecutive cell divisions, or by simultaneous gain of chromosomes in a single mitosis.
  • These data strongly suggest that hyperdiploidy in childhood ALL generally arises by a simultaneous gain of all additional chromosomes in a single abnormal mitosis.
  • [MeSH-major] Diploidy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Cell Division. Child. Genetic Markers. Humans. In Situ Hybridization, Fluorescence. Microsatellite Repeats / genetics. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942938.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


19. Shman TV, Belevtsev MV, Buglova SE: [Drug sensitivity of tumor cells in varieties of acute childhood leukemia]. Vopr Onkol; 2005;51(5):558-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Drug sensitivity of tumor cells in varieties of acute childhood leukemia].
  • Drug sensitivity of tumor cells was studied in 154 children diagnosed with acute leukemia.
  • Cellular sensitivity in acute lymphoblastic leukemia (ALL) was higher than in acute myeloid one (AML), while T-line ALL cells were more sensitive to dexamethasone than those of B-line.
  • It was suggested that lower drug sensitivity of ALL cells at the earlier stages of cell differentiation was due to their reduced susceptibility to apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756010.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7006-34-0 / Asparagine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


20. Ito R, Asami S, Motohashi S, Ootsuka S, Yamaguchi Y, Chin M, Shichino H, Yoshida Y, Nemoto N, Mugishima H, Suzuki T: Significance of survivin mRNA expression in prognosis of neuroblastoma. Biol Pharm Bull; 2005 Apr;28(4):565-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroblastoma (NB) is the most common malignant solid tumor in childhood, and among all childhood malignancies is second in prevalence only to leukemia.
  • We investigated its expression by reverse transcription-polymerase chain reaction (RT-PCR) in NB cell lines (SK-N-SH, NB-39, and IMR-32), two normal blood cell samples, and 13 clinical NB tumor samples.
  • All three NB cell lines had high levels of mRNA expression for this gene, but normal blood cells had no expression.
  • [MeSH-minor] Cell Line, Tumor. Child. Child, Preschool. Humans. Infant. Inhibitor of Apoptosis Proteins. Neoplasm Recurrence, Local. Neoplasm Staging. Nuclear Proteins / metabolism. Oncogene Proteins / metabolism. Prognosis. Receptor, trkA / metabolism. Recurrence

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15802787.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / MYCN protein, human; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, trkA
  •  go-up   go-down


21. Matsuura S, Matsumoto Y, Morishima K, Izumi H, Matsumoto H, Ito E, Tsutsui K, Kobayashi J, Tauchi H, Kajiwara Y, Hama S, Kurisu K, Tahara H, Oshimura M, Komatsu K, Ikeuchi T, Kajii T: Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome. Am J Med Genet A; 2006 Feb 15;140(4):358-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer-prone syndrome of premature chromatid separation (PCS syndrome) with mosaic variegated aneuploidy (MVA) is a rare autosomal recessive disorder characterized by growth retardation, microcephaly, childhood cancer, premature chromatid separation of all chromosomes, and mosaicism for various trisomies and monosomies.
  • [MeSH-minor] Amino Acid Sequence. Blotting, Western. Cdc20 Proteins. Cell Cycle Proteins / genetics. Cell Cycle Proteins / metabolism. Cells, Cultured. Child. Child, Preschool. Female. Fluorescent Antibody Technique. Humans. Infant. Kinetochores / metabolism. Male. Molecular Sequence Data. Mosaicism. Protein-Serine-Threonine Kinases. Reverse Transcriptase Polymerase Chain Reaction. Sequence Homology, Amino Acid. Syndrome

  • Genetics Home Reference. consumer health - BUB1B gene.
  • Coriell Cell Repositories. culture/stock collections - Coriell Cell Repositories .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16411201.001).
  • [ISSN] 1552-4825
  • [Journal-full-title] American journal of medical genetics. Part A
  • [ISO-abbreviation] Am. J. Med. Genet. A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdc20 Proteins; 0 / Cell Cycle Proteins; 156288-95-8 / CDC20 protein, human; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / BUB1 protein, human; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


22. Baade PD, Youlden DR, Valery PC, Hassall T, Ward L, Green AC, Aitken JF: Trends in incidence of childhood cancer in Australia, 1983-2006. Br J Cancer; 2010 Feb 2;102(3):620-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in incidence of childhood cancer in Australia, 1983-2006.
  • BACKGROUND: There are few population-based childhood cancer registries in the world containing stage and treatment data.
  • METHODS: Data from the population-based Australian Paediatric Cancer Registry were used to calculate incidence rates during the most recent 10-year period (1997-2006) and trends in incidence between 1983 and 2006 for the 12 major diagnostic groups of the International Classification of Childhood Cancer.
  • RESULTS: In the period 1997-2006, there were 6184 childhood cancer (at 0-14 years) cases in Australia (157 cases per million children).
  • Since 1983, there have been significant increases among boys and girls for leukaemia, and hepatic and germ-cell tumours, whereas for boys, incidence of neuroblastomas and malignant epithelial tumours has recently decreased.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Blood Cancer. 2009 Jul;53(1):13-6 [19260104.001]
  • [Cites] Eur J Cancer. 2009 Mar;45(5):747-55 [19117750.001]
  • [Cites] Epidemiology. 2009 Jul;20(4):475-83 [19373093.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1583-92 [14506117.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Nov;25(11):854-63 [14608194.001]
  • [Cites] Eur J Cancer. 2004 Jun;40(9):1351-60 [15177495.001]
  • [Cites] Int J Cancer. 1996 Jan 3;65(1):34-8 [8543393.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77 [9731733.001]
  • [Cites] Pediatr Blood Cancer. 2004 Dec;43(7):749-57 [15390289.001]
  • [Cites] Lancet. 2004 Dec 11-17;364(9451):2074-6 [15589293.001]
  • [Cites] Lancet. 2004 Dec 11-17;364(9451):2097-105 [15589307.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1457-67 [15712273.001]
  • [Cites] Lancet. 2005 Jun 18-24;365(9477):2088 [15964441.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):1020-31 [15986434.001]
  • [Cites] Paediatr Drugs. 2006;8(2):71-84 [16608369.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):841-8 [16886175.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:29-53 [17119192.001]
  • [Cites] Int J Epidemiol. 2006 Dec;35(6):1495-503 [17008361.001]
  • [Cites] J Natl Cancer Inst. 2007 May 16;99(10):790-800 [17505074.001]
  • [Cites] Arch Dis Child. 2007 Oct;92(10):890-7 [17566053.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):416-32 [18074355.001]
  • [Cites] Pediatr Clin North Am. 2008 Feb;55(1):251-73, xiii [18242324.001]
  • [Cites] Cancer. 2008 Feb 1;112(3):461-72 [18072274.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1859-67 [18076067.001]
  • [Cites] J Pediatr. 2008 Apr;152(4):458-66 [18346496.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Feb;30(2):153-9 [18376269.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2607-11 [18324630.001]
  • [Cites] Pediatrics. 2008 Jun;121(6):e1470-7 [18519450.001]
  • [Cites] West Afr J Med. 2008 Jan;27(1):3-6 [18689295.001]
  • [Cites] J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79 [18812549.001]
  • [Cites] Environ Health Perspect. 2009 Feb;117(2):299-302 [19270803.001]
  • [Cites] Pediatr Blood Cancer. 2009 Jul;53(1):1-2 [19326404.001]
  • (PMID = 20051948.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2822940
  •  go-up   go-down


23. Kikuchi A, Maeda M, Hanada R, Okimoto Y, Ishimoto K, Kaneko T, Ikuta K, Tsuchida M, Tokyo Children's Cancer Study Group (TCCSG): Moyamoya syndrome following childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Mar;48(3):268-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Moyamoya syndrome following childhood acute lymphoblastic leukemia.
  • BACKGROUND: Long-term survivors of childhood acute lymphoblastic leukemia (ALL) sometimes suffer from adverse long-term sequelae.
  • We analyzed the incidence, clinical course and prognosis of moyamoya syndrome (MoS) following childhood ALL.
  • None of the patients had central nervous system (CNS) leukemia.
  • [MeSH-major] Cranial Irradiation / adverse effects. Moyamoya Disease / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16615044.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


24. Nagai K, Yamamoto K, Fujiwara H, An J, Ochi T, Suemori K, Yasumi T, Tauchi H, Koh K, Sato M, Morimoto A, Heike T, Ishii E, Yasukawa M: Subtypes of familial hemophagocytic lymphohistiocytosis in Japan based on genetic and functional analyses of cytotoxic T lymphocytes. PLoS One; 2010;5(11):e14173
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Familial hemophagocytic lymphohistiocytosis (FHL) is a rare disease of infancy or early childhood.
  • [MeSH-minor] Blotting, Western. Cell Degranulation / immunology. Cells, Cultured. Child. Cytotoxicity, Immunologic / immunology. DNA Mutational Analysis. Female. Flow Cytometry. Humans. Infant. Infant, Newborn. Japan. Male. Membrane Proteins / genetics. Munc18 Proteins / genetics. Munc18 Proteins / metabolism. Mutation. Perforin. Polymerase Chain Reaction. Pore Forming Cytotoxic Proteins / genetics

  • Genetic Alliance. consumer health - Hemophagocytic Lymphohistiocytosis (HLH).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Cell Biol. 2005 Dec;15(12):644-50 [16260137.001]
  • [Cites] J Hum Genet. 2005;50(11):600-3 [16180048.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2316-23 [16778144.001]
  • [Cites] Nat Rev Immunol. 2006 Dec;6(12):940-52 [17124515.001]
  • [Cites] Pediatr Blood Cancer. 2007 Feb;48(2):124-31 [16937360.001]
  • [Cites] Int J Hematol. 2007 Jul;86(1):58-65 [17675268.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1906-15 [17525286.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:495-517 [17506701.001]
  • [Cites] Traffic. 2008 Sep;9(9):1414-24 [18445120.001]
  • [Cites] Cell Immunol. 2009;254(2):149-54 [18835598.001]
  • [Cites] Science. 2009 Jan 23;323(5913):474-7 [19164740.001]
  • [Cites] Am J Hum Genet. 2009 Oct;85(4):482-92 [19804848.001]
  • [Cites] J Clin Invest. 2009 Dec;119(12):3765-73 [19884660.001]
  • [Cites] Science. 1999 Dec 3;286(5446):1957-9 [10583959.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2352-5 [10733506.001]
  • [Cites] Am J Hum Genet. 2001 Mar;68(3):590-7 [11179007.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):98-106 [11252968.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):761-9 [11564062.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):346-9 [11841437.001]
  • [Cites] J Immunol. 2003 Feb 15;170(4):2205-13 [12574394.001]
  • [Cites] Trends Cell Biol. 2003 Apr;13(4):177-86 [12667755.001]
  • [Cites] Br J Haematol. 2003 May;121(3):503-10 [12716377.001]
  • [Cites] Cell. 2003 Nov 14;115(4):461-73 [14622600.001]
  • [Cites] J Med Genet. 2004 Oct;41(10):763-7 [15466010.001]
  • [Cites] Eur J Pediatr. 1983 Jun-Jul;140(3):221-30 [6354720.001]
  • [Cites] Semin Oncol. 1991 Feb;18(1):29-33 [1992521.001]
  • [Cites] Semin Oncol. 1991 Feb;18(1):34-8 [1992522.001]
  • [Cites] J Pediatr. 1997 Mar;130(3):337-8 [9063402.001]
  • [Cites] Pathology. 1997 Feb;29(1):92-5 [9094188.001]
  • [Cites] Am J Hum Genet. 1999 Jan;64(1):165-71 [9915955.001]
  • [Cites] Am J Hum Genet. 1999 Jan;64(1):172-9 [9915956.001]
  • [Cites] J Cell Sci. 1999 Mar;112 ( Pt 6):845-54 [10036234.001]
  • [Cites] Hum Mol Genet. 2005 Mar 15;14(6):827-34 [15703195.001]
  • [Cites] Blood. 2005 May 1;105(9):3442-8 [15632205.001]
  • [Cites] Pediatr Blood Cancer. 2006 Apr;46(4):482-8 [16365863.001]
  • (PMID = 21152410.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Munc18 Proteins; 0 / PRF1 protein, human; 0 / Pore Forming Cytotoxic Proteins; 0 / STXBP2 protein, human; 0 / UNC13D protein, human; 126465-35-8 / Perforin
  • [Other-IDs] NLM/ PMC2994802
  •  go-up   go-down


25. Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, Benoit Y, Biondi A, Cavé H, Dombret H, Fielding AK, Foà R, Gökbuget N, Goldstone AH, Goulden N, Henze G, Hoelzer D, Janka-Schaub GE, Macintyre EA, Pieters R, Rambaldi A, Ribera JM, Schmiegelow K, Spinelli O, Stary J, von Stackelberg A, Kneba M, Schrappe M, van Dongen JJ, European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL), International Berlin-Frankfurt-Münster Study Group (I-BFM-SG): Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia; 2010 Mar;24(3):521-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification.
  • For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR- and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.
  • The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033054.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 92
  •  go-up   go-down


26. Okamoto S, Machinami R, Tanizawa T, Matsumoto S, Lee GH, Ishikawa Y: Dedifferentiated liposarcoma with rhabdomyoblastic differentiation in an 8-year-old girl. Pathol Res Pract; 2010 Mar 15;206(3):191-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of a liposarcoma during childhood is extremely rare.
  • [MeSH-minor] Cell Differentiation. Child. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Proto-Oncogene Proteins c-mdm2 / genetics. Thigh / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19515501.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


27. Wang Q, Liu H, Zhang X, Liu Q, Xing Y, Zhou X, Tong C, Zhu P: High doses of mother's lymphocyte infusion to treat EBV-positive T-cell lymphoproliferative disorders in childhood. Blood; 2010 Dec 23;116(26):5941-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High doses of mother's lymphocyte infusion to treat EBV-positive T-cell lymphoproliferative disorders in childhood.
  • In 54 cases when a child required cytotherapy or hematopoietic stem cell transplantation, we studied the mother for child-mother microchimerism with use of insertion-deletion polymorphisms as allogeneic markers and a combination of nested polymerase chain reaction (PCR) and real-time quantitative PCR.
  • Among them, 5 children had non-transplant-associated, EBV(+) T-cell LPD.
  • We suggest that high doses of mother's lymphocyte infusion may be an effective and safe treatment for non-transplant-associated EBV(+) T-cell LPD.
  • [MeSH-minor] Adolescent. Child. Chimerism. DNA, Viral / genetics. Female. Hematopoietic Stem Cell Transplantation. Herpesvirus 4, Human / pathogenicity. Humans. Immunotherapy, Adoptive. Male. Remission Induction. Sex-Determining Region Y Protein. Transplantation, Homologous. Watchful Waiting

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20926772.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / SRY protein, human; 0 / Sex-Determining Region Y Protein
  •  go-up   go-down


28. Pawels EK, Volterrani D: Fatty acid facts, Part I. Essential fatty acids as treatment for depression, or food for mood? Drug News Perspect; 2008 Oct;21(8):446-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A higher dietary intake of omega-6 results in the excessive incorporation of these molecules in the cell membrane with numerous pathological consequences, presumably due to the formation of proinflammatory eicosanoids.
  • The omega-3 series members docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) provide fluidity to the cell membrane, facilitating certain processes including neurotransmission and ion channel flow.
  • There is no evidence that fatty acid monotherapy has a mood-elevating effect, with a possible exception for childhood depression.
  • There are indications that omega-3 has a prophylactic effect on perinatal depression and has a negative effect on natural killer cell activity and T-lymphocyte function.

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Mood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved.
  • (PMID = 19034351.001).
  • [ISSN] 0214-0934
  • [Journal-full-title] Drug news & perspectives
  • [ISO-abbreviation] Drug News Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Fatty Acids, Essential; 0 / Fatty Acids, Omega-3; 0 / Fatty Acids, Omega-6
  • [Number-of-references] 50
  •  go-up   go-down


29. Gao YJ, Zhu XH, Yang Y, Wu Y, Lu FJ, Zhai XW, Wang HS: Prevalence of ETV6-RUNX1 fusion gene in children with acute lymphoblastic leukemia in China. Cancer Genet Cytogenet; 2007 Oct 1;178(1):57-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of ETV6-RUNX1 fusion gene in children with acute lymphoblastic leukemia in China.
  • A series of 92 Chinese children newly diagnosed with acute lymphoblastic leukemia (ALL) were examined for the ETV6-RUNX1 (previously TEL-AML1) fusion gene by using a nested reverse transcriptase-polymerase chain reaction.
  • ETV6-RUNX1 fusion transcripts were detected in 21 of 92 patients (22.8%): 16 with common ALL, 4 with precursor B-cell ALL, and 1 with T-ALL.
  • The prevalence of ETV6-RUNX1 positivity was 24.7% (20/81) in childhood B-lineage ALL.
  • The prevalence of ETV6-RUNX1 in Chinese pediatric ALL patients proved to be similar to that found in other countries.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / biosynthesis. Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / biosynthesis. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / biosynthesis. Repressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889709.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / RUNX1 protein, human; 0 / Repressor Proteins
  •  go-up   go-down


30. Kosulin K, Haberler C, Hainfellner JA, Amann G, Lang S, Lion T: Investigation of adenovirus occurrence in pediatric tumor entities. J Virol; 2007 Jul;81(14):7629-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of adenovirus occurrence in pediatric tumor entities.
  • We have therefore employed a real-time quantitative PCR (RQ-PCR) assay permitting highly sensitive detection of all 51 currently known human AdV serotypes to screen more than 500 tumor specimens derived from 17 different childhood cancer entities including leukemias, lymphomas, and solid tumors.


31. Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, Tolle G, Happich M, Muckenthaler MU, Kulozik AE: Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood; 2006 Aug 15;108(4):1151-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.
  • Activating mutations of the transmembrane receptor NOTCH1 are common in precursor T-cell lymphoblastic leukemia (T-ALL).
  • We systematically analyzed the impact of activating NOTCH1 mutations on early treatment response and long-term outcome in 157 patients with T-ALL of the pediatric ALL-Berlin-Frankfurt-Munster (BFM) 2000 study.
  • The presence of NOTCH1 mutations was significantly correlated with a good prednisone response and favorable minimal residual disease (MRD) kinetics, which was independent from sex, age, white blood cell count, and T-cell immunophenotype at the time of diagnosis.
  • [MeSH-major] Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614245.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


32. Parera VE, Koole RH, Minderman G, Edixhoven A, Rossetti MV, Batlle A, de Rooij FW: Novel null-allele mutations and genotype-phenotype correlation in Argentinean patients with erythropoietic protoporphyria. Mol Med; 2009 Nov-Dec;15(11-12):425-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinically, EPP is characterized by photosensitivity that begins in early childhood and includes burning, swelling, itching, and painful erythema in sun-exposed areas.

  • Genetic Alliance. consumer health - Erythropoietic Protoporphyria.
  • Genetic Alliance. consumer health - Protoporphyria.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2001 Jun;47(6):1112-3 [11375302.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):27-8 [11753383.001]
  • [Cites] J Invest Dermatol. 2001 Dec;117(6):1521-5 [11886517.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2002 Feb;48(1):91-6 [11929053.001]
  • [Cites] J Hum Genet. 2003;48(2):70-6 [12601550.001]
  • [Cites] Mol Genet Metab. 2003 Sep-Oct;80(1-2):196-206 [14567969.001]
  • [Cites] Hum Genet. 2004 Feb;114(3):256-62 [14669009.001]
  • [Cites] J Med Genet. 2004 Aug;41(8):e105 [15286165.001]
  • [Cites] Hum Genet. 1986 Aug;73(4):320-6 [3017841.001]
  • [Cites] Clin Chem. 1986 Dec;32(12):2137-42 [3779978.001]
  • [Cites] Clin Chem. 1988 Dec;34(12):2481-5 [3197287.001]
  • [Cites] Biomed Chromatogr. 1987;2(4):164-8 [3507230.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Dec 14;173(2):748-55 [2260980.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Dec 16;181(2):594-9 [1755842.001]
  • [Cites] Genomics. 1991 Dec;11(4):1152-4 [1783383.001]
  • [Cites] Eur J Biochem. 1992 Apr 1;205(1):217-22 [1555582.001]
  • [Cites] Am J Hum Genet. 1992 Jun;50(6):1203-10 [1376018.001]
  • [Cites] Am J Hum Genet. 1996 Feb;58(2):292-9 [8571955.001]
  • [Cites] J Invest Dermatol. 1996 Feb;106(2):346-50 [8601739.001]
  • [Cites] J Invest Dermatol. 1997 Nov;109(5):688-91 [9347801.001]
  • [Cites] Am J Hum Genet. 1998 Jun;62(6):1341-52 [9585598.001]
  • [Cites] J Invest Dermatol. 1998 Sep;111(3):406-9 [9740232.001]
  • [Cites] Blood. 1999 Mar 15;93(6):2105-10 [10068685.001]
  • [Cites] Lancet. 1961 Aug 26;2(7200):448-51 [13765301.001]
  • [Cites] Liver Transpl. 2005 Dec;11(12):1590-6 [16315313.001]
  • [Cites] Mol Genet Metab. 2007 Apr;90(4):402-7 [17196862.001]
  • [Cites] Arch Dermatol. 2007 Sep;143(9):1125-9 [17875872.001]
  • [Cites] J Hepatol. 2008 Feb;48(2):375-9 [18160121.001]
  • [Cites] Br J Dermatol. 2008 Jul;159(1):182-91 [18460026.001]
  • (PMID = 19693296.001).
  • [ISSN] 1528-3658
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 4.99.1.1 / Ferrochelatase
  •  go-up   go-down


33. Guastadisegni MC, Lonoce A, Impera L, Albano F, D'Addabbo P, Caruso S, Vasta I, Panagopoulos I, Leszl A, Basso G, Rocchi M, Storlazzi CT: Bone marrow ectopic expression of a non-coding RNA in childhood T-cell acute lymphoblastic leukemia with a novel t(2;11)(q11.2;p15.1) translocation. Mol Cancer; 2008;7:80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow ectopic expression of a non-coding RNA in childhood T-cell acute lymphoblastic leukemia with a novel t(2;11)(q11.2;p15.1) translocation.
  • T-cell acute lymphoblastic leukemia (T-ALL) is associated with a large number of such rearrangements.
  • We report the ectopic expression of the 3' portion of EST DA926692 in the bone marrow of a childhood T-ALL case showing a t(2;11)(q11.2;p15.1) translocation as the sole chromosome abnormality.
  • Bioinformatic analysis excluded that this small non-coding RNA is a precursor of micro-RNA, although it is conceivable that it has a different, yet unknown, functional role.
  • [MeSH-major] Bone Marrow / metabolism. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 2 / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. RNA, Untranslated / genetics. Translocation, Genetic


34. Mejstríková E, Kalina T, Trka J, Starý J, Hrusák O: Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy. Leukemia; 2005 Jun;19(6):1092-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD / immunology. Antigens, Differentiation, Myelomonocytic / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15830012.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3
  •  go-up   go-down


35. Allmendinger J, Paradies F, Kamprad M, Richter T, Pustowoit B, Liebert UG: Determination of rubella virus-specific cell-mediated immunity using IFN gamma-ELISpot. J Med Virol; 2010 Feb;82(2):335-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of rubella virus-specific cell-mediated immunity using IFN gamma-ELISpot.
  • The results from both, ELISA and ELISpot were independent of previous encounter to RV (vaccination, exanthematous disease, or childhood infection).
  • Considering both humoral and cell-mediated immune responses, a positive RV immune reaction was seen in 98.6%.

  • Genetic Alliance. consumer health - Rubella.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 20029797.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antigens, Viral; 0 / Immunoglobulin G; 0 / Virosomes; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


36. Strefford JC, Worley H, Barber K, Wright S, Stewart AR, Robinson HM, Bettney G, van Delft FW, Atherton MG, Davies T, Griffiths M, Hing S, Ross FM, Talley P, Saha V, Moorman AV, Harrison CJ: Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization. Oncogene; 2007 Jun 21;26(29):4306-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization.
  • Chromosomal abnormalities are important for the classification and risk stratification of patients with acute lymphoblastic leukemia (ALL).
  • However, approximately 30% of childhood and 50% of adult patients lack abnormalities with clinical relevance.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Profiling. Genome, Human. Leukemia-Lymphoma, Adult T-Cell / genetics. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237825.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


37. Attarbaschi A, Mann G, König M, Steiner M, Strehl S, Schreiberhuber A, Schneider B, Meyer C, Marschalek R, Borkhardt A, Pickl WF, Lion T, Gadner H, Haas OA, Dworzak MN: Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity. Clin Cancer Res; 2006 May 15;12(10):2988-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity.
  • PURPOSE: Mixed lineage leukemia (MLL) abnormalities occur in approximately 50% of childhood pro-B acute lymphoblastic leukemia (ALL).
  • RESULTS: We found that 15 of 29 pro-B ALL, 7 of 11 CD10- pre-B ALL, and 1 of 2 French-American-British classification L1 mature B-cell leukemia cases had a MLL rearrangement.
  • CONCLUSIONS: The striking similarities between the two CD10- ALL subsets imply that CD10- pre-B ALL variants may represent pro-B ALL cases that maintained the propensity to rearrange and express their immunoglobulin heavy chain rather than actual pre-B ALL forms transformed at this later stage of B-cell differentiation.
  • [MeSH-major] Chromosome Aberrations. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707593.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


38. Ghoussaini M, Stutzmann F, Couturier C, Vatin V, Durand E, Lecoeur C, Degraeve F, Heude B, Tauber M, Hercberg S, Levy-Marchal C, Tounian P, Weill J, Traurig M, Bogardus C, Baier LJ, Michaud JL, Froguel P, Meyre D: Analysis of the SIM1 contribution to polygenic obesity in the French population. Obesity (Silver Spring); 2010 Aug;18(8):1670-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A nominal evidence of association was found for the nonsynonymous variant P352T C/A (rs3734354) (P = 0.01, OR = 0.81 (0.70-0.95)), the +2,004 TGA -/insT SNP (rs35180395) (P = 0.02, OR = 1.21 (1.02-1.43)), the +2,215A/G TGA SNP (rs9386126) (P = 0.002, OR = 0.81 (0.71-0.93)), and pooled childhood/adult obesity.

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2000 Jan 1;9(1):101-8 [10587584.001]
  • [Cites] Diabetes. 2009 Jul;58(7):1682-9 [19401419.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 Dec;24(12):1608-17 [11126213.001]
  • [Cites] Hum Mol Genet. 2001 Jul 1;10(14):1465-73 [11448938.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10236-43 [11782478.001]
  • [Cites] Hum Mol Genet. 2002 Aug 15;11(17):1997-2004 [12165561.001]
  • [Cites] Am J Hum Genet. 2004 Mar;74(3):572-81 [14973783.001]
  • [Cites] Diabetes. 2004 Mar;53(3):803-11 [14988267.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2004 Jul;287(1):E105-13 [14982752.001]
  • [Cites] Eur J Clin Nutr. 1991 Jan;45(1):13-21 [1855495.001]
  • [Cites] Acta Paediatr. 1995 Aug;84(8):961-3 [7488831.001]
  • [Cites] Control Clin Trials. 1998 Aug;19(4):336-51 [9683310.001]
  • [Cites] Genes Dev. 1998 Oct 15;12(20):3264-75 [9784500.001]
  • [Cites] Cell. 2005 Nov 4;123(3):493-505 [16269339.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2437-40 [16595598.001]
  • [Cites] J Neurosci. 2006 Jun 28;26(26):7116-20 [16807340.001]
  • [Cites] Endocrinology. 2006 Oct;147(10):4542-9 [16709610.001]
  • [Cites] Endocrinology. 2006 Oct;147(10):4539-41 [16980439.001]
  • [Cites] Mol Endocrinol. 2006 Oct;20(10):2483-92 [16728530.001]
  • [Cites] Int J Obes (Lond). 2007 Mar;31(3):429-34 [16924270.001]
  • [Cites] Hum Mol Genet. 2007 Aug 1;16(15):1837-44 [17519222.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):768-75 [18454148.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2008 Oct;4(10):569-77 [18779842.001]
  • [Cites] Nat Genet. 2009 Jan;41(1):18-24 [19079260.001]
  • [Cites] Nat Genet. 2009 Jan;41(1):25-34 [19079261.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):157-9 [19151714.001]
  • [Cites] Mech Dev. 2000 Feb;90(2):253-61 [10640708.001]
  • (PMID = 20075856.001).
  • [ISSN] 1930-739X
  • [Journal-full-title] Obesity (Silver Spring, Md.)
  • [ISO-abbreviation] Obesity (Silver Spring)
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0600331; United States / Intramural NIH HHS / / ZIA DK069075-12
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Repressor Proteins; 0 / SIM1 protein, human
  • [Other-IDs] NLM/ NIHMS236778; NLM/ PMC2953787
  •  go-up   go-down


39. Hattori H, Suminoe A, Wada M, Koga Y, Kohno K, Okamura J, Hara T, Matsuzaki A: Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukemia. Leuk Res; 2007 Dec;31(12):1633-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukemia.
  • The aim of this study is to determine whether the polymorphisms of the MDR1 gene are associated with the development of childhood acute lymphoblastic leukemia (ALL).
  • The present study suggests that the genetic background of MDR1 may be associated with the development of childhood ALL, possibly due to a quantitative change in the MDR1 gene resulting from genetic polymorphisms.
  • [MeSH-major] P-Glycoprotein / genetics. Polymorphism, Genetic / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17568669.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / RNA, Messenger
  •  go-up   go-down


40. Ishiguro H, Yasuda Y, Hyodo H, Tomita Y, Koike T, Shinagawa T, Shimizu T, Morimoto T, Hattori K, Matsumoto M, Inoue H, Yabe H, Yabe M, Shinohara O, Kato S: Growth and Endocrine Function in Long-term Adult Survivors of Childhood Stem Cell Transplant. Clin Pediatr Endocrinol; 2009;18(1):1-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth and Endocrine Function in Long-term Adult Survivors of Childhood Stem Cell Transplant.
  • The number of long-term surviving stem cell transplant (SCT) recipients has increased steadily, and attention has now extended to the late complications of this procedure.
  • The objective of this study was to investigate relationship among growth and endocrine functions in long-term adult survivors of childhood SCT.
  • The mean loss of height for all patients who received SCT during childhood was estimated to be approximately 1 SDS/6.5 yr (r=0.517).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24790374.001).
  • [ISSN] 0918-5739
  • [Journal-full-title] Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
  • [ISO-abbreviation] Clin Pediatr Endocrinol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC4004878
  • [Keywords] NOTNLM ; endocrine function / growth disorder / long-term adult survivors
  •  go-up   go-down


41. Forestier E, Schmiegelow K, Nordic Society of Paediatric Haematology and Oncology NOPHO: The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations. J Pediatr Hematol Oncol; 2006 Aug;28(8):486-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations.
  • The correlation between age and karyotype was studied in 1425, 0 to 14.9 years old children who were diagnosed with acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia.
  • Almost 80% of the non-Down B-cell precursor ALL cases in the 2 to 7 years frequency peak group who had aberrant cytogenetic results had either a high-hyperdiploid clone (51 to 61 chromosomes) or a translocation t(12;21)(p13;q22).
  • Among B-cell precursor ALL cases, high white blood cell counts correlated with earlier age at diagnosis (rS=-0.23; P<0.001) being most evident for 11q23/MLL-aberrations, translocation t(12;21)(p13;q22), and high-hyperdiploidy.
  • Among acute myeloblastic leukemia patients, frequency peaks were found for those with MLL/11q23 rearrangements (peak: first year), Down syndrome (peak: second to third year), or cytogenetic abnormalities other than translocations t(8;21), t(15;17), and inv(16)/t(16;16) (peak: first to third year).
  • The epidemiology of the cytogenetic subsets of acute leukemias questions whether age as a disease-related prognostic parameter has any relevance in childhood leukemia clinical research beyond being a surrogate marker for more important, truly biologic features such as cytogenetic aberrations and white cell count at diagnosis.
  • Further research is needed to explore whether the 2 to 7 years age incidence peak in childhood ALL harbor yet unidentified cytogenetic subsets with the same natural history as the high-hyperdiploid and t(12;21)-positive leukemias.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912588.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Nathan PC, Whitcomb T, Wolters PL, Steinberg SM, Balis FM, Brouwers P, Hunsberger S, Feusner J, Sather H, Miser J, Odom LF, Poplack D, Reaman G, Bleyer WA: Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P. Leuk Lymphoma; 2006 Dec;47(12):2488-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P.
  • Between 1977 and 1991, the Children's Cancer Group and the National Cancer Institute conducted three trials of very high-dose methotrexate (33.6 g/m2; VHD-MTX) in place of cranial radiation (CRT) as central nervous system (CNS) preventive therapy, and assessed efficacy, acute toxicity and long-term neurocognitive outcome.
  • CCG-134P evaluated the addition of intensified systemic and intrathecal therapy to VHD-MTX in 128 patients with high-risk acute lymphoblastic leukemia (ALL) and demonstrated reduced CNS relapse compared to the CCG-191P trial, but equivalent survival.
  • VHD-MTX achieved similar survival to other CNS-directed therapies without the long-term impact on intelligence, but with substantial acute toxicities.
  • [MeSH-major] Central Nervous System Neoplasms / prevention & control. Methotrexate / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


43. Carlet M, Janjetovic K, Rainer J, Schmidt S, Panzer-Grümayer R, Mann G, Prelog M, Meister B, Ploner C, Kofler R: Expression, regulation and function of phosphofructo-kinase/fructose-biphosphatases (PFKFBs) in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia cells. BMC Cancer; 2010 Nov 23;10:638
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression, regulation and function of phosphofructo-kinase/fructose-biphosphatases (PFKFBs) in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia cells.
  • BACKGROUND: Glucocorticoids (GCs) cause apoptosis and cell cycle arrest in lymphoid cells and constitute a central component in the therapy of lymphoid malignancies, most notably childhood acute lymphoblastic leukemia (ALL).
  • RESULTS: Expression analyses in additional ALL children, non-leukemic individuals and leukemic cell lines confirmed frequent PFKFB2 induction by GC in most systems sensitive to GC-induced apoptosis, particularly T-ALL cells.
  • Conditional PFKFB2 over-expression in the CCRF-CEM T-ALL in vitro model revealed that its 2 splice variants (PFKFB2-15A and PFKFB2-15B) had no detectable effect on cell survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Dexamethasone / therapeutic use. Glucocorticoids / therapeutic use. Lymphocytes / drug effects. Phosphofructokinase-2 / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Animals. Cell Survival. Child. Doxycycline / pharmacology. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Leukemic / drug effects. Humans. Jurkat Cells. Male. Oligonucleotide Array Sequence Analysis. Rats. Time Factors. Transfection

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Dec 1;86(11):4199-205 [7492778.001]
  • [Cites] FASEB J. 2005 Mar;19(3):434-6 [15637111.001]
  • [Cites] Eur J Biochem. 1998 May 15;254(1):103-10 [9652401.001]
  • [Cites] Oncogene. 1999 Aug 12;18(32):4626-31 [10467407.001]
  • [Cites] Mol Cell. 2000 Sep;6(3):683-92 [11030347.001]
  • [Cites] Trends Biochem Sci. 2001 Jan;26(1):30-5 [11165514.001]
  • [Cites] Cell Death Differ. 2002 Jan;9(1):6-19 [11803370.001]
  • [Cites] Nat Immunol. 2002 Jun;3(6):515-21 [12032565.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):110-9 [12127395.001]
  • [Cites] Cell Death Differ. 2004 Jul;11 Suppl 1:S45-55 [15243581.001]
  • [Cites] Biochem J. 2004 Aug 1;381(Pt 3):561-79 [15170386.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Trends Biochem Sci. 2004 Nov;29(11):586-92 [15501677.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30927-33 [10521487.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):348-53 [7812967.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2061-9 [16293608.001]
  • [Cites] FASEB J. 2006 Dec;20(14):2600-2 [17077285.001]
  • [Cites] Leukemia. 2008 Feb;22(2):370-7 [18046449.001]
  • [Cites] Mol Cell Endocrinol. 2009 Mar 5;300(1-2):7-16 [19000736.001]
  • [Cites] Blood. 2009 Feb 26;113(9):2014-21 [18978206.001]
  • [Cites] Leukemia. 2009 Apr;23(4):820-3 [19151768.001]
  • [Cites] Science. 2009 May 22;324(5930):1029-33 [19460998.001]
  • [Cites] Leukemia. 2009 Nov;23(11):2167-70 [19657369.001]
  • [Cites] Leuk Res. 2010 Apr;34(4):529-34 [19631983.001]
  • [Cites] Nat Rev Cancer. 2010 Apr;10(4):267-77 [20300106.001]
  • [Cites] Leukemia. 2003 Jan;17(1):17-25 [12529655.001]
  • [Cites] EMBO J. 1995 Feb 1;14(3):452-60 [7859735.001]
  • [Cites] Science. 1995 Jun 23;268(5218):1766-9 [7792603.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Mar 30;143(3):1092-8 [3032183.001]
  • [Cites] J Biol Chem. 1988 Nov 15;263(32):16796-801 [2846551.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Clin Exp Immunol. 1992 May;88(2):341-4 [1572099.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2429-37 [9395239.001]
  • (PMID = 21092265.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / W 1101
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; 0 / PFKFB4 protein, human; 7S5I7G3JQL / Dexamethasone; EC 2.7.1.105 / PFKFB2 protein, human; EC 2.7.1.105 / PFKFB3 protein, human; EC 2.7.1.105 / Phosphofructokinase-2; N12000U13O / Doxycycline
  • [Other-IDs] NLM/ PMC3002928
  •  go-up   go-down


44. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Coustan-Smith E, Kun LE, Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML, Boyett JM, Leung W, Handgretinger R, Downing JR, Evans WE, Relling MV: Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med; 2009 Jun 25;360(26):2730-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating childhood acute lymphoblastic leukemia without cranial irradiation.
  • BACKGROUND: Prophylactic cranial irradiation has been a standard treatment in children with acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) relapse.
  • CNS leukemia (CNS-3 status) or a traumatic lumbar puncture with blast cells at diagnosis and a high level of minimal residual disease (> or = 1%) after 6 weeks of remission induction were significantly associated with poorer event-free survival.
  • Risk factors for CNS relapse included the genetic abnormality t(1;19)(TCF3-PBX1), any CNS involvement at diagnosis, and T-cell immunophenotype.
  • CONCLUSIONS: With effective risk-adjusted chemotherapy, prophylactic cranial irradiation can be safely omitted from the treatment of childhood ALL. (ClinicalTrials.gov number, NCT00137111. )
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Asparaginase / administration & dosage. Asparaginase / adverse effects. Central Nervous System Neoplasms / drug therapy. Child. Child, Preschool. Combined Modality Therapy. Cranial Irradiation. Cyclophosphamide / administration & dosage. Daunorubicin / administration & dosage. Dexamethasone / administration & dosage. Hematopoietic Stem Cell Transplantation. Humans. Infant. Methotrexate / adverse effects. Remission Induction / methods. Risk Factors. Secondary Prevention. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Massachusetts Medical Society
  • [Cites] Leukemia. 2002 Jun;16(6):1099-111 [12040440.001]
  • [Cites] JAMA. 2002 Oct 23-30;288(16):2001-7 [12387652.001]
  • [Cites] J Natl Cancer Inst. 2008 Sep 17;100(18):1301-9 [18780868.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):184-8 [12525508.001]
  • [Cites] Blood. 2003 May 15;101(10):3809-17 [12531809.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2736-40 [12843002.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2001-7 [14559953.001]
  • [Cites] Br J Haematol. 2004 Jan;124(1):33-46 [14675406.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):314-9 [8321259.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):177-9 [7799017.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2786-91 [9256120.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] Leukemia. 2000 Aug;14(8):1354-61 [10942229.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3381-4 [11071631.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2196-204 [11187911.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2257-66 [11187917.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2267-75 [11187918.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Sep;48(3):235-40 [11592346.001]
  • [Cites] Blood. 2002 Feb 1;99(3):825-33 [11806983.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2734-9 [11929760.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Blood. 1999 May 1;93(9):2817-23 [10216075.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):110-7 [15630450.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):734-45 [15952999.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7161-7 [16192600.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2332-6 [16710032.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3142-9 [16809737.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1165-73 [16609069.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Blood. 2007 Feb 1;109(3):896-904 [17003366.001]
  • [Cites] JAMA. 2007 Mar 21;297(11):1207-15 [17374815.001]
  • [Cites] Blood. 2007 May 15;109(10):4151-7 [17264302.001]
  • [Cites] JAMA. 2007 Jun 27;297(24):2705-15 [17595271.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4914-21 [17971588.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4022-9 [17720883.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):257-68 [18308251.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1932-9 [18421047.001]
  • [Cites] Blood. 2008 May 1;111(9):4477-89 [18285545.001]
  • [CommentIn] N Engl J Med. 2009 Sep 24;361(13):1310; author reply 1311-2 [19776415.001]
  • [CommentIn] N Engl J Med. 2009 Sep 24;361(13):1310-1; author reply 1311-2 [19780213.001]
  • (PMID = 19553647.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00137111
  • [Grant] United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; United States / NCI NIH HHS / CA / CA36401; United States / NCI NIH HHS / CA / R01 CA051001-13; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA78224; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA60419; United States / NIGMS NIH HHS / GM / GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NIGMS NIH HHS / GM / U01 GM061393-090007; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA036401; United States / NCI NIH HHS / CA / CA51001; United States / NCI NIH HHS / CA / U01 CA060419
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS118392; NLM/ PMC2754320
  •  go-up   go-down


45. Styczynski J, Wysocki M, Debski R, Czyzewski K, Kolodziej B, Rafinska B, Kubicka M, Koltan S, Koltan A, Pogorzala M, Kurylak A, Olszewska-Slonina D, Balwierz W, Juraszewska E, Wieczorek M, Olejnik I, Krawczuk-Rybak M, Kuzmicz M, Kowalczyk J, Stefaniak J, Badowska W, Sonta-Jakimczyk D, Szczepanski T, Matysiak M, Malinowska I, Stanczak E, Wachowiak J, Konatkowska B, Gil L, Balcerska A, Maciejka-Kapuscinska L: Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J Cancer Res Clin Oncol; 2007 Nov;133(11):875-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia.
  • PURPOSE: Cellular resistance in childhood acute leukemias might be related to profile and function of multidrug resistance proteins and apoptosis regulating proteins.
  • (2) correlation with ex vivo drug resistance, and (3) analysis of their prognostic impact on clinical outcome in childhood acute lymphoblastic (ALL) and acute myeloid (AML) leukemia.
  • CONCLUSIONS: The phenomenon of cellular drug resistance in childhood acute leukemias is multifactorial and plays an important role in response to therapy.
  • Expression of MRP1, PGP and LRP proteins, as well as their co-expression play possible role in childhood relapsed ALL.
  • [MeSH-major] Drug Resistance, Multiple. Drug Resistance, Neoplasm. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Vault Ribonucleoprotein Particles / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Cancer Res Clin Oncol. 2007 Nov;133(11):895. Wachowiak, Jacek [added]; Konatkowska, Benigna [added]; Gil, Lidia [added]; Balcerska, Anna [added]; Maciejka-Kapuscinska, Lucyna [added]
  • [Cites] Med Pediatr Oncol. 2002 Jun;38(6):379-86 [11984797.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):2253-8 [16158972.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3120-6 [11595704.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Jan-Feb;22(1):45-9 [10695821.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3352-60 [12384437.001]
  • [Cites] Leukemia. 1994 Jul;8(7):1224-9 [8035616.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2125-9 [16281077.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):85-95 [12691146.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2092-8 [9490695.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):647-55 [9722289.001]
  • [Cites] Leukemia. 1995 Nov;9(11):1864-9 [7475276.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4493-8 [12816874.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):264-79 [15491285.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):963-4 [14990658.001]
  • [Cites] Pediatr Int. 1999 Dec;41(6):641-7 [10618884.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3861-8 [7579354.001]
  • [Cites] Leukemia. 1999 Dec;13(12):2023-30 [10602424.001]
  • [Cites] Pediatr Blood Cancer. 2004 Feb;42(2):195-9 [14752887.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2879-86 [11023525.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 1999 Nov;38(11):760-3 [11798719.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2723-9 [9326239.001]
  • [Cites] Klin Padiatr. 2005 Nov-Dec;217(6):310-20 [16307416.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1843-8 [12685842.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1083-6 [12631611.001]
  • [Cites] Br J Haematol. 1999 Jun;105(4):876-82 [10554796.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2025-9 [16304569.001]
  • [Cites] Leuk Lymphoma. 1994 Apr;13(3-4):187-201 [8049644.001]
  • [Cites] Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110 [10739113.001]
  • [Cites] Klin Padiatr. 1987 May-Jun;199(3):151-60 [3306129.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2117-24 [16107894.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3262-8 [12947061.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Curr Opin Oncol. 1995 Jan;7(1):36-44 [7696362.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2387-94 [12816873.001]
  • [Cites] Expert Rev Mol Diagn. 2004 Sep;4(5):705-13 [15347263.001]
  • [Cites] J Endocrinol. 2003 Jul;178(1):19-27 [12844332.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 2002 Mar;41(3):183-5 [11940320.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8661-8 [16361551.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):599-604 [10404077.001]
  • [Cites] Sao Paulo Med J. 2004 Jul 1;122(4):166-71 [15543372.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):875-9 [12153178.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Ai Zheng. 2005 Aug;24(8):1015-7 [16086885.001]
  • [Cites] Exp Hematol. 1998 Nov;26(12):1111-7 [9808049.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2063-71 [16107896.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):321-7 [10050715.001]
  • [Cites] Exp Hematol. 2002 Nov;30(11):1302-8 [12423683.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 17671794.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


46. Steck AK, Baschal EE, Jasinski JM, Boehm BO, Bottini N, Concannon P, Julier C, Morahan G, Noble JA, Polychronakos C, She JX, Eisenbarth GS, Type I Diabetes Genetics Consortium: rs2476601 T allele (R620W) defines high-risk PTPN22 type I diabetes-associated haplotypes with preliminary evidence for an additional protective haplotype. Genes Immun; 2009 Dec;10 Suppl 1:S21-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] rs2476601 T allele (R620W) defines high-risk PTPN22 type I diabetes-associated haplotypes with preliminary evidence for an additional protective haplotype.
  • Protein tyrosine phosphatase non-receptor type 22 (PTPN22) is the third major locus affecting risk of type I diabetes (T1D), after HLA-DR/DQ and INS.
  • The most associated single-nucleotide polymorphism (SNP), rs2476601, has a C->T variant and results in an arginine (R) to tryptophan (W) amino acid change at position 620.
  • To assess whether this, or other specific variants, are responsible for T1D risk, the Type I Diabetes Genetics Consortium analyzed 28 PTPN22 SNPs in 2295 affected sib-pair (ASP) families.
  • Transmission Disequilibrium Test analyses of haplotypes revealed that all three haplotypes with a T allele at rs2476601 were overtransmitted to affected children, and two of these three haplotypes showed statistically significant overtransmission (P=0.003 to P=5.9E-12).
  • Another haplotype had decreased transmission to affected children (P=3.5E-05).
  • All haplotypes containing the rs2476601 T allele were identical for all SNPs across PTPN22 and only varied at centromeric SNPs.
  • When considering rs2476601 'C' founder chromosomes, a second haplotype (AGGGGC) centromeric of PTPN22 in the C1orf178 region was associated with protection from T1D (odds ratio=0.81, P=0.0005).
  • This novel finding requires replication in independent populations.
  • We conclude the major association of PTPN22 with T1D is likely due to the recognized non-synonymous SNP rs2476601 (R620W).
  • [MeSH-major] Diabetes Mellitus, Type 1 / genetics. Genetic Predisposition to Disease. Haplotypes. Polymorphism, Single Nucleotide. Protein Tyrosine Phosphatase, Non-Receptor Type 22 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Immunol. 2005 Jan;66(1):60-4 [15620463.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Nov;89(11):5862-5 [15531553.001]
  • [Cites] Diabetes. 2005 Mar;54(3):906-8 [15734872.001]
  • [Cites] J Med Genet. 2005 Mar;42(3):266-70 [15744042.001]
  • [Cites] Am J Hum Genet. 2005 Apr;76(4):561-71 [15719322.001]
  • [Cites] Nat Genet. 2005 Dec;37(12):1317-9 [16273109.001]
  • [Cites] Am J Med Genet A. 2006 Mar 15;140(6):586-93 [16470599.001]
  • [Cites] Diabetologia. 2006 Jun;49(6):1198-208 [16614815.001]
  • [Cites] Diabetes. 2006 Oct;55(10):2883-9 [17003357.001]
  • [Cites] Pediatr Diabetes. 2006 Oct;7(5):274-8 [17054449.001]
  • [Cites] Diabetes. 2007 Feb;56(2):522-6 [17259401.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):661-78 [17554300.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4704-10 [17878369.001]
  • [Cites] Diabetes. 2008 Jan;57(1):229-34 [17934143.001]
  • [Cites] J Autoimmun. 2008 Aug;31(1):13-21 [18299186.001]
  • [Cites] Diabetes. 2008 Jun;57(6):1730-7 [18305142.001]
  • [Cites] Cell Death Differ. 2003 Feb;10(2):185-92 [12700646.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):97-101 [11731797.001]
  • [Cites] Genes Immun. 2009 Dec;10 Suppl 1:S5-S15 [19956101.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):337-8 [15004560.001]
  • [Cites] Am J Hum Genet. 2004 Sep;75(3):504-7 [15273934.001]
  • [Cites] Am J Hum Genet. 2004 Aug;75(2):330-7 [15208781.001]
  • [Cites] Diabetes. 2004 Nov;53(11):3020-3 [15504986.001]
  • [Cites] Am J Hum Genet. 1995 Aug;57(2):487-98 [7668275.001]
  • [Cites] J Exp Med. 1999 Jan 4;189(1):111-21 [9874568.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • (PMID = 19956096.001).
  • [ISSN] 1476-5470
  • [Journal-full-title] Genes and immunity
  • [ISO-abbreviation] Genes Immun.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK061722; United States / NIDDK NIH HHS / DK / U01 DK062418; United States / NIDDK NIH HHS / DK / U01 DK062418; United States / NIDDK NIH HHS / DK / U01 DK062418-06; United States / NCRR NIH HHS / RR / U54 RR020278; United States / NCRR NIH HHS / RR / U54 RR020278; United States / NCRR NIH HHS / RR / U54 RR020278-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.3.48 / PTPN22 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 22
  • [Other-IDs] NLM/ NIHMS163336; NLM/ PMC2805459
  •  go-up   go-down


47. An Q, Xue TY, Xu W, Gao JZ, Wu Y, Xu CP: [Effect of N-tosyl-L-phenylalnylchloromethyl ketone and dexamethasone on expression of nuclear transcription factor-kappaB in childhood acute lymphoblastic leukemia and its significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr;15(2):399-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of N-tosyl-L-phenylalnylchloromethyl ketone and dexamethasone on expression of nuclear transcription factor-kappaB in childhood acute lymphoblastic leukemia and its significance].
  • In order to investigate the effect of N-tosyl-L-phenylalnylchloromethyl ketone (TPCK) and dexamethasone (Dex) on expression of nuclear transcription factor-kappaB (NF-kappaB) in childhood acute lymphoblastic leukemia (ALL) and its significance, so as to provide the experimental basis for corresponding clinical treatment of ALL, in which NF-kappaB is taken as a target.
  • The biotin-streptavidin method was used to detect the expression of NF-kappaB P65 protein and the effects of TPCK and Dex at clinically relevant dosage on activity of NF-kappaB P65 protein in 20 childhood ALL patients.
  • Inhibition of NF-kappaB conduction pathway may have a significant value in childhood ALL treatment.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493356.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Protein Synthesis Inhibitors; 402-71-1 / Tosylphenylalanyl Chloromethyl Ketone; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


48. Quigley DI, Wolff DJ: Pediatric T-cell acute lymphoblastic leukemia with aberrations of both MLL loci. Cancer Genet Cytogenet; 2006 Jul 1;168(1):77-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric T-cell acute lymphoblastic leukemia with aberrations of both MLL loci.
  • Translocations involving the MLL gene at 11q23 have been implicated in acute lymphoblastic leukemia (ALL), as well as acute myeloid leukemia (AML).
  • Such translocations result in gain of function fusion proteins that drive cell proliferation.
  • Except in cases of T-cell ALL, MLL rearrangement is typically associated with a poor prognosis.
  • We report a case of T-cell ALL with a t(11;19)(q23;p13.3) and deletion of the other chromosome 11 homolog at band q23.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Gene Deletion. Leukemia-Lymphoma, Adult T-Cell / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16772125.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


49. Breton CV, Vora H, Salam MT, Islam T, Wenten M, Gauderman WJ, Van den Berg D, Berhane K, Peters JM, Gilliland FD: Variation in the GST mu locus and tobacco smoke exposure as determinants of childhood lung function. Am J Respir Crit Care Med; 2009 Apr 1;179(7):601-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation in the GST mu locus and tobacco smoke exposure as determinants of childhood lung function.

  • MedlinePlus Health Information. consumer health - Secondhand Smoke.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1043-50 [10613335.001]
  • [Cites] Am J Hum Genet. 2007 Dec;81(6):1158-68 [17966093.001]
  • [Cites] Thorax. 2000 Apr;55(4):271-6 [10722765.001]
  • [Cites] Genetics. 2000 Jun;155(2):945-59 [10835412.001]
  • [Cites] Clin Chest Med. 2000 Dec;21(4):633-43 [11194775.001]
  • [Cites] Cytogenet Cell Genet. 2000;91(1-4):234-8 [11173863.001]
  • [Cites] Int J Occup Med Environ Health. 2001;14(2):99-113 [11548073.001]
  • [Cites] Hum Hered. 2002;53(2):79-91 [12037407.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2225-9 [12029063.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Jul 1;166(1):76-84 [12091175.001]
  • [Cites] Lung Cancer. 2002 Aug;37(2):143-6 [12140136.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Aug 1;166(3):323-8 [12153964.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Aug 15;166(4):457-63 [12186820.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Sep 1;166(5):710-6 [12204870.001]
  • [Cites] Monaldi Arch Chest Dis. 2003 Apr-Jun;59(2):103-7 [14635497.001]
  • [Cites] Thorax. 2004 Jan;59(1):8-10 [14694237.001]
  • [Cites] Br J Clin Pharmacol. 2004 Feb;57(2):213-7 [14748821.001]
  • [Cites] Pharmacogenetics. 2004 May;14(5):295-301 [15115915.001]
  • [Cites] N Engl J Med. 2004 Sep 9;351(11):1057-67 [15356303.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5643-8 [8242618.001]
  • [Cites] Br Med Bull. 1997 Jan;53(1):40-57 [9158283.001]
  • [Cites] Genet Epidemiol. 1998;15(2):173-81 [9554554.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):914-20 [9797707.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Mar;159(3):760-7 [10051248.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Mar;159(3):768-75 [10051249.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):185-8 [10067818.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):99-104 [15665284.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:51-88 [15822171.001]
  • [Cites] Proc Am Thorac Soc. 2005;2(1):50-60 [16113469.001]
  • [Cites] PLoS Med. 2006 Apr;3(4):e91 [16509765.001]
  • [Cites] Biochem Pharmacol. 2006 Jun 28;72(1):115-23 [16678797.001]
  • [Cites] Paediatr Respir Rev. 2006 Jun;7(2):103-9 [16765295.001]
  • [Cites] Proc Am Thorac Soc. 2006 Nov;3(8):668-72 [17065371.001]
  • [Cites] Respir Res. 2007;8:2 [17217536.001]
  • [Cites] Lancet. 2007 Feb 17;369(9561):571-7 [17307103.001]
  • [Cites] Pharmacol Ther. 2007 May;114(2):129-45 [17408750.001]
  • [Cites] Genet Epidemiol. 2007 Jul;31(5):383-95 [17410554.001]
  • [Cites] Allergy Asthma Proc. 2007 May-Jun;28(3):282-6 [17619555.001]
  • [Cites] Mutat Res. 2007 Sep 1;633(1):1-12 [17644396.001]
  • [Cites] Chest. 2007 Aug;132(2):651-6 [17699136.001]
  • [Cites] Pediatr Dev Pathol. 2007 Sep-Oct;10(5):335-47 [17929994.001]
  • [Cites] Early Hum Dev. 2007 Nov;83(11):707-11 [17889457.001]
  • [Cites] Am J Med Sci. 2007 Nov;334(5):361-80 [18004091.001]
  • [Cites] Hum Mol Genet. 2008 Sep 15;17(18):2834-48 [18593715.001]
  • [Cites] Arch Toxicol. 2009 Apr;83(4):351-6 [18668224.001]
  • [Cites] Neurobiol Aging. 2010 Jan;31(1):34-45 [18423940.001]
  • [Cites] Neurology. 2000 Feb 8;54(3):552-7 [10680782.001]
  • (PMID = 19151192.001).
  • [ISSN] 1535-4970
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / 5R01HL61768; United States / NIEHS NIH HHS / ES / 5P01 ES011627; United States / NHLBI NIH HHS / HL / 1R01HL76647; United States / NIEHS NIH HHS / ES / 5P01 ES009581; United States / NIEHS NIH HHS / ES / 5P30 ES007048
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tobacco Smoke Pollution; EC 2.5.1.18 / GSTM3 protein, human; EC 2.5.1.18 / GSTM4 protein, human; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M5, human; EC 2.5.1.18 / glutathione S-transferase Mu 2
  • [Other-IDs] NLM/ PMC2720124
  •  go-up   go-down


50. Hu RH, Lu Y, Li QH, Ma L, Li B, Zhu XF, Wang JX, Pang TX: [Relationship between midkine expression and drug efflux in childhood acute lymphoblastic leukemia cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec;17(6):1502-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between midkine expression and drug efflux in childhood acute lymphoblastic leukemia cells].
  • This study was aimed to investigate the expression of midkine gene in childhood acute lymphoblastic leukemia patients (ALL) and to explore the possible effects of midkine gene on the chemotherapeutic drug efflux.
  • The rhodamine 123 efflux test revealed that MFI in the leukemia cells was obviously lower than that in normal cells (p < 0.01), furthermore, there was an evident negative correlation between the MFI and MK mRNA expression (r = -0.869, p < 0.001).
  • It is concluded that there is powerful drug efflux ability in lymphoblastic leukemia cells with high midkine gene expression.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20030935.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / MDK protein, human; 0 / Nerve Growth Factors; 0 / RNA, Messenger
  •  go-up   go-down


51. Furushima W, Inagaki M, Gunji A, Kaga M, Yamazaki H, Horiguchi T: [Evaluation of preclinical onset in patients with the childhood form of cerebral adrenoleukodystrophy--usefulness of visual cognitive function and evoked potential tests]. No To Hattatsu; 2008 Jul;40(4):301-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of preclinical onset in patients with the childhood form of cerebral adrenoleukodystrophy--usefulness of visual cognitive function and evoked potential tests].
  • 0SD) after hematopoietic stem cell transplantation.
  • These cognitive and neurophysiological examinations could be useful in the detection of preclinical onset of childhood ALD before the appearance of MRI lesions on MRI.

  • Genetic Alliance. consumer health - Adrenoleukodystrophy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18634415.001).
  • [ISSN] 0029-0831
  • [Journal-full-title] No to hattatsu. Brain and development
  • [ISO-abbreviation] No To Hattatsu
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


52. Wu S, Gessner R, Taube T, Korte A, von Stackelberg A, Kirchner R, Henze G, Seeger K: Chemokine IL-8 and chemokine receptor CXCR3 and CXCR4 gene expression in childhood acute lymphoblastic leukemia at first relapse. J Pediatr Hematol Oncol; 2006 Apr;28(4):216-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine IL-8 and chemokine receptor CXCR3 and CXCR4 gene expression in childhood acute lymphoblastic leukemia at first relapse.
  • In this study, we examined the gene expression of interleukin (IL)-8, CXCR3, and CXCR4 in leukemic cells from 100 children with relapsed B-cell progenitors (BCP) acute lymphoblastic leukemia (ALL), using quantitative real-time polymerase chain reaction (RT-PCR).
  • [MeSH-major] Bone Marrow / pathology. Gene Expression Regulation, Neoplastic. Interleukin-8 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, CXCR4 / genetics. Receptors, Chemokine / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16679918.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCR3 protein, human; 0 / DNA Primers; 0 / Interleukin-8; 0 / RNA, Neoplasm; 0 / Receptors, CXCR3; 0 / Receptors, CXCR4; 0 / Receptors, Chemokine
  •  go-up   go-down


53. von Stackelberg A, Hartmann R, Bührer C, Fengler R, Janka-Schaub G, Reiter A, Mann G, Schmiegelow K, Ratei R, Klingebiel T, Ritter J, Henze G, ALL-REZ BFM Study Group: High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Blood; 2008 Mar 1;111(5):2573-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.
  • High-dose methotrexate (MTX) has been extensively used for treatment of acute lymphoblastic leukemia (ALL).
  • To determine the optimal dose of MTX in childhood relapsed ALL, the ALL Relapse Berlin-Frankfurt-Münster (ALL-REZ BFM) Study Group performed this prospective randomized study.
  • A total of 269 children with a first early/late isolated (n = 156) or combined (n = 68) bone marrow or any isolated extramedullary relapse (n = 45) of precursor B-cell (PBC) ALL (excluding very early marrow relapse within 18 months after initial diagnosis) were registered at the ALL-REZ BFM90 trial and randomized to receive methotrexate infusions at either 1 g/m(2) over 36 hours (intermediate dose, ID) or 5 g/m(2) over 24 hours (high dose, HD) during 6 (or 4) intensive polychemotherapy courses.
  • Fifty-five children received stem-cell transplants.
  • In conclusion, methotrexate infusions at 5 g/m(2) per 24 hours, compared with 1 g/m(2) per 36 hours, are not associated with increased disease control in relapsed childhood PBC acute lymphoblastic leukemia.
  • [MeSH-major] Methotrexate / administration & dosage. Methotrexate / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2008 Aug 1;112(3):910 [18650464.001]
  • (PMID = 18089849.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


54. Michels AW, Nakayama M: The anti-insulin trimolecular complex in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes; 2010 Aug;17(4):329-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Understanding of the structural interaction between MHC molecules, antigenic peptides, and T-cell receptors (the three components of the trimolecular complex) has increased greatly over the past several years.
  • [MeSH-minor] Animals. Autoantibodies / blood. Autoantibodies / physiology. Humans. Major Histocompatibility Complex / immunology. Mice. Models, Biological. Receptors, Antigen, T-Cell / metabolism. Receptors, Antigen, T-Cell / physiology

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Apr 21;288(5465):505-11 [10775108.001]
  • [Cites] Am J Hum Genet. 2000 Feb;66(2):740-3 [10677335.001]
  • [Cites] Nat Immunol. 2001 Jun;2(6):501-7 [11376336.001]
  • [Cites] J Immunol. 2001 Nov 1;167(9):4926-35 [11673498.001]
  • [Cites] J Immunol. 2002 Feb 1;168(3):1235-43 [11801660.001]
  • [Cites] Diabetes. 2002 May;51(5):1383-90 [11978634.001]
  • [Cites] Diabetes. 2002 Jul;51(7):2126-34 [12086942.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2436-43 [12193712.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1395-401 [12376594.001]
  • [Cites] J Exp Med. 2003 Jun 16;197(12):1635-44 [12796471.001]
  • [Cites] Diabetes. 2004 Aug;53(8):1987-94 [15277377.001]
  • [Cites] J Clin Invest. 2004 Aug;114(4):589-97 [15314696.001]
  • [Cites] Nat Immunol. 2004 Oct;5(10):1028-35 [15378058.001]
  • [Cites] Science. 1983 Dec 23;222(4630):1337-9 [6362005.001]
  • [Cites] Eur J Immunol. 1994 Aug;24(8):1853-7 [8056042.001]
  • [Cites] Eur J Immunol. 1995 Apr;25(4):1056-62 [7537670.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):956-60 [8570667.001]
  • [Cites] Diabetes. 1997 Jan;46(1):34-9 [8971078.001]
  • [Cites] Nat Genet. 1997 Mar;15(3):293-7 [9054945.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2518-21 [9122227.001]
  • [Cites] Tissue Antigens. 1999 Jan;53(1):101-5 [10082436.001]
  • [Cites] Immunity. 2005 Jan;22(1):81-92 [15664161.001]
  • [Cites] Nat Immunol. 2005 May;6(5):490-6 [15821740.001]
  • [Cites] Nature. 2005 May 12;435(7039):220-3 [15889095.001]
  • [Cites] Nature. 2005 May 12;435(7039):224-8 [15889096.001]
  • [Cites] Diabetes. 2005 Jul;54(7):2053-9 [15983206.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10581-6 [16030147.001]
  • [Cites] J Clin Invest. 2005 Aug;115(8):2268-76 [16075062.001]
  • [Cites] Adv Immunol. 2005;87:123-62 [16102573.001]
  • [Cites] EMBO J. 2005 Sep 7;24(17):2968-79 [16079912.001]
  • [Cites] J Exp Med. 2005 Nov 7;202(9):1191-7 [16260488.001]
  • [Cites] J Autoimmun. 2005 Nov;25(3):193-8 [16289958.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18425-30 [16339897.001]
  • [Cites] Diabetologia. 2006 May;49(5):953-7 [16520917.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1371-81 [16628253.001]
  • [Cites] Diabetes. 2006 Jun;55(6):1862-8 [16731854.001]
  • [Cites] Diabetes. 2006 Jul;55(7):1978-84 [16804066.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2226-36 [16878175.001]
  • [Cites] J Clin Invest. 2006 Dec;116(12):3258-65 [17143333.001]
  • [Cites] J Immunol. 2007 May 15;178(10):6051-7 [17475829.001]
  • [Cites] Nat Genet. 2007 Jul;39(7):857-64 [17554260.001]
  • [Cites] J Clin Invest. 2007 Jul;117(7):1835-43 [17607359.001]
  • [Cites] J Immunol. 2007 Aug 15;179(4):2082-8 [17675466.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):975-83 [17694060.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):887-92 [18004301.001]
  • [Cites] Diabetes. 2008 Mar;57(3):770-6 [18065518.001]
  • [Cites] J Immunol. 2008 Mar 15;180(6):3849-56 [18322192.001]
  • [Cites] Diabetes. 2008 Apr;57(4):1084-92 [18252895.001]
  • [Cites] Lancet. 2008 May 24;371(9626):1777-82 [18502302.001]
  • [Cites] Diabetes. 2008 Jul;57(7):1852-60 [18398138.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10090-4 [18626021.001]
  • [Cites] Science. 2008 Aug 8;321(5890):843-7 [18687966.001]
  • [Cites] J Clin Invest. 2008 Oct;118(10):3390-402 [18802479.001]
  • [Cites] Clin Exp Immunol. 2009 May;156(2):226-31 [19292763.001]
  • [Cites] J Immunol. 2009 Jul 1;183(1):59-65 [19535636.001]
  • [Cites] Nat Immunol. 2009 Sep;10(9):1026-33 [19668219.001]
  • [Cites] EMBO J. 2009 Sep 16;28(18):2812-24 [19680229.001]
  • [Cites] Immunity. 2009 Oct 16;31(4):643-53 [19818656.001]
  • [Cites] J Immunol. 2009 Dec 1;183(11):7585-91 [19917704.001]
  • [Cites] J Immunol. 2010 Jan 15;184(2):658-65 [19966211.001]
  • [Cites] Nat Immunol. 2010 Mar;11(3):225-31 [20139986.001]
  • [Cites] Nat Immunol. 2010 Apr;11(4):350-4 [20190756.001]
  • [Cites] J Clin Invest. 2001 Jan;107(2):173-80 [11160133.001]
  • (PMID = 20489610.001).
  • [ISSN] 1752-2978
  • [Journal-full-title] Current opinion in endocrinology, diabetes, and obesity
  • [ISO-abbreviation] Curr Opin Endocrinol Diabetes Obes
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK095995; United States / NIDDK NIH HHS / DK / R00 DK080885
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Insulin; 0 / Macromolecular Substances; 0 / Receptors, Antigen, T-Cell
  • [Number-of-references] 63
  • [Other-IDs] NLM/ NIHMS577707; NLM/ PMC4012426
  •  go-up   go-down


55. Truong TH, Beyene J, Hitzler J, Abla O, Maloney AM, Weitzman S, Sung L: Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome. Cancer; 2007 Oct 15;110(8):1832-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome.
  • BACKGROUND: Tumor lysis syndrome (TLS) is a well-recognized complication of acute lymphoblastic leukemia (ALL).
  • The objectives of the current study were 1) to describe the prevalence and predictors of TLS in childhood ALL and 2) to develop a sensitive prediction rule to identify patients at lower risk of TLS.
  • Factors predictive of TLS were male sex (odds ratio [OR], 1.8; P = .041), age >/=10 years (OR, 4.5; P < .0001), splenomegaly (OR, 3.3; P < .0001), mediastinal mass (OR, 12.2; P < .0001), T-cell phenotype (OR, 8.2; P < .0001), central nervous system involvement (OR, 2.8; P = .026), lactate dehydrogenase >/=2000 U/L (OR, 7.6; P < .0001), and white blood count (WBC) >/=20 x 10(9)/L (OR, 4.7; P < .0001).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Tumor Lysis Syndrome / diagnosis


56. Thörn I, Forestier E, Thuresson B, Wasslavik C, Malec M, Li A, Lindström-Eriksson E, Botling J, Barbany G, Jacobsson S, Olofsson T, Porwit A, Sundström C, Rosenquist R: Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002-2006. Eur J Haematol; 2010 Feb 1;84(2):117-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002-2006.
  • Minimal residual disease (MRD) detection during the early treatment phase has become an important stratification parameter in many childhood acute lymphoblastic leukaemia (ALL) treatment protocols.
  • From 334 childhood ALL cases diagnosed during 2002-2006, we analysed 279 diagnostic samples (84%) by screening for rearranged immunoglobulin (IG) and T-cell receptor (TCR) genes.
  • Overall, clonal IG/TCR rearrangements were detected in 97% (236/244) of B-cell precursor ALL (BCP ALL) and 94% (33/35) of T-ALL.
  • Taken together, this national retrospective study demonstrates that an IG/TCR target for MRD monitoring can be identified in the majority of childhood ALL cases, whereas identification of a second sensitive target gene needs to be improved.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Monitoring, Physiologic / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895569.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


57. Smith A, Roman E, Simpson J, Ansell P, Fear NT, Eden T: Childhood leukaemia and socioeconomic status: fact or artefact? A report from the United Kingdom childhood cancer study (UKCCS). Int J Epidemiol; 2006 Dec;35(6):1504-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leukaemia and socioeconomic status: fact or artefact? A report from the United Kingdom childhood cancer study (UKCCS).
  • BACKGROUND: It is widely believed that children of high socioeconomic status (SES) are more likely than those of low SES to develop acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Socioeconomic Factors
  • [MeSH-minor] Adolescent. Bias (Epidemiology). Case-Control Studies. Child. Child, Preschool. Female. Great Britain / epidemiology. Humans. Infant. Leukemia / epidemiology. Male. Psychosocial Deprivation. Risk Factors. Social Class. Social Mobility

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Epidemiol. 2007 Aug;36(4):929 [17670774.001]
  • (PMID = 16945940.001).
  • [ISSN] 0300-5771
  • [Journal-full-title] International journal of epidemiology
  • [ISO-abbreviation] Int J Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


58. Zhang B, Tie LJ, Ye QD, Gu LJ, Tang JY, Yuan XL, Shen LS: [Expression of the transcription factor PAX5 in childhood acute leukemic cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb;14(1):6-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of the transcription factor PAX5 in childhood acute leukemic cells].
  • To investigate transcription factor PAX5 expression characteristics in childhood acute leukemic cells, expression levels of PAX5 and CD19 mRNA in 6 hematological tumor cell lines and bone marrow cells of 6 normal children, 58 de novo patients and 4 relapse acute leukemic children, including 39 cases of B-ALL, 10 cases of T-ALL and 13 cases of AML, were detected by a real-time RT-PCR.
  • The results showed that PAX5 and CD19 mRNA expression levels were 2.35% and 2.52% in Namalwa (B-cell lines) respectively, but almost not detectable in other T- and myeloid cell lines.
  • As binding sites for B-cell specific activator protein have been identified in the promoter regions of CD19, the study found that in B-ALL, there was clear correlation between the expression levels of PAX5 and CD19, which was also studied by real-time RT-PCR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584581.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / B-Cell-Specific Activator Protein; 0 / PAX5 protein, human; 0 / RNA, Messenger; 0 / Transcription Factors
  •  go-up   go-down


59. Milde T, Oehme I, Korshunov A, Kopp-Schneider A, Remke M, Northcott P, Deubzer HE, Lodrini M, Taylor MD, von Deimling A, Pfister S, Witt O: HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res; 2010 Jun 15;16(12):3240-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.
  • PURPOSE: Medulloblastomas are the most common malignant brain tumors in childhood.
  • This study investigated the expression levels of individual human HDAC family members in primary medulloblastoma samples, their potential as risk stratification markers, and their roles in tumor cell growth.
  • Immunohistochemistry revealed a strong expression of HDAC5 and HDAC9 proteins in most of all primary medulloblastomas investigated. siRNA-mediated knockdown of HDAC5 or HDAC9 in medulloblastoma cells resulted in decreased cell growth and cell viability.
  • Because our functional studies point toward a role in medulloblastoma cell growth, HDAC5 and HDAC9 may potentially be novel drug targets.
  • [MeSH-minor] Cell Proliferation. Gene Knockdown Techniques. Humans. Prognosis. Risk. Tumor Cells, Cultured. Up-Regulation

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • (PMID = 20413433.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Repressor Proteins; EC 3.5.1.98 / HDAC5 protein, human; EC 3.5.1.98 / HDAC9 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


60. Cario G, Zimmermann M, Romey R, Gesk S, Vater I, Harbott J, Schrauder A, Moericke A, Izraeli S, Akasaka T, Dyer MJ, Siebert R, Schrappe M, Stanulla M: Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood; 2010 Jul 01;115(26):5393-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.
  • High-level expression of the cytokine receptor-like factor 2 gene, CRLF2, in precursor B-cell acute lymphoblastic leukemia (pB-ALL) was shown to be caused by a translocation involving the IGH@ locus or a deletion juxtaposing CRLF2 with the P2RY8 promoter.
  • To assess its possible prognostic value, CRLF2 expression was analyzed in 555 childhood pB-ALL patients treated according to the Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster 2000 (ALL-BFM 2000) protocol.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Cytokine / genetics. Receptors, Purinergic P2 / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Non Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20378752.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRLF2 protein, human; 0 / Receptors, Cytokine; 0 / Receptors, Purinergic P2
  •  go-up   go-down


61. Gulten T, Yakut T, Karkucak M, Baytan B, Guneş AM: AML1 amplification and 17q25 deletion in a case of childhood acute lymphoblastic leukemia. J Clin Lab Anal; 2009;23(6):368-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AML1 amplification and 17q25 deletion in a case of childhood acute lymphoblastic leukemia.
  • We report a case of childhood acute lymphoblastic leukemia (ALL) with both acute myeloid leukemia 1 (AML1) amplification and 17q25 deletion.
  • AML1 amplification is a common finding in childhood ALL, and itis observed as an increase in gene copy number by the FISH analysis.
  • The 17q25 is a gene-rich chromosomal location and distinct abnormalities of this region have been observed in previous cases of different kinds of leukemia.
  • Deletion of the 17q25 region has been reported in two leukemia patients.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 17 / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Gene Amplification / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927343.001).
  • [ISSN] 1098-2825
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human
  •  go-up   go-down


62. Luo XQ, Ke ZY, Huang LB, Guan XQ, Zhang YC, Zhang XL: High-risk childhood acute lymphoblastic leukemia in China: factors influencing the treatment and outcome. Pediatr Blood Cancer; 2009 Feb;52(2):191-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-risk childhood acute lymphoblastic leukemia in China: factors influencing the treatment and outcome.
  • OBJECTIVE: Acute lymphoblastic leukemia (ALL) with high-risk features has an inferior outcome.
  • Factors influencing the treatment and outcome of pediatric ALL with high-risk features in developing countries have not been well studied.
  • METHODS: High-risk features were defined as: age <1 year or >10 years, white blood cell (WBC) > 50 x 10(9)/L, CNS or testicular involvement at diagnosis, T-ALL, BCR-ABL/MLL-AF4, poor prednisone response, slow early response to induction chemotherapy which was defined as M3 status (>25% blasts) on day 15 bone marrow with age >6 years or presenting WBC > 20 x 10(9)/L at diagnosis and/or non-remission (NR) after 33 days of induction therapy.
  • CONCLUSION: A decreased treatment-related death frequency was associated with an improved outcome of leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology


63. Moreno DA, Scrideli CA, Cortez MA, de Paula Queiroz R, Valera ET, da Silva Silveira V, Yunes JA, Brandalise SR, Tone LG: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol; 2010 Sep;150(6):665-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia.
  • We evaluated the mRNA gene expression profile of 12 HDAC genes by quantitative real-time polymerase chain reaction in 94 consecutive childhood acute lymphoblastic leukaemia (ALL) samples and its association with clinical/biological features and survival.
  • Our data suggest that higher expression of HDAC7 and HDAC9 is associated with poor prognosis in childhood ALL and could be promising therapeutic targets for the treatment of refractory childhood ALL.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Histone Deacetylases / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20636436.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; EC 3.5.1.98 / HDAC7 protein, human; EC 3.5.1.98 / HDAC9 protein, human; EC 3.5.1.98 / Histone Deacetylases; EC 3.5.1.98 / histone deacetylase 3
  •  go-up   go-down


64. Huang L, Lequin M, Pieters R, van den Heuvel-Eibrink MM: The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma. Pediatr Blood Cancer; 2007 Apr;48(4):468-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma.
  • BACKGROUND: The aim of this study was to evaluate the value of follow-up investigations of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin's lymphoma (T-NHL), including cerebrospinal fluid (CSF) examination, bone marrow (BM) aspiration, peripheral blood (PB) count, serum lactate dehydrogenase (LDH) and chest X-rays in patients with an initial mediastinal enlargement.
  • PROCEDURE: We reviewed clinical records of all T-ALL patients from 1987 to 2002 and all T-NHL patients from 1977 to 2002, seen at a single institution.
  • All T-ALL and T-NHL patients with a mediastinal relapse were symptomatic.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, T-Cell / diagnosis


65. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD: Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol; 2010 Oct;11(10):950-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
  • Dexrazoxane reduces cardiac damage during treatment with doxorubicin in children with acute lymphoblastic leukaemia (ALL).
  • We aimed to establish the long-term effect of dexrazoxane on the subclinical state of cardiac health in survivors of childhood high-risk ALL 5 years after completion of doxorubicin treatment.

  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Heart. 2008 Apr;94(4):525-33 [18347383.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(2):CD003917 [18425895.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3777-84 [18669466.001]
  • [Cites] Am J Cardiol. 2008 Sep 15;102(6):761-6 [18774003.001]
  • [Cites] Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1311-7 [19018683.001]
  • [Cites] Cancer. 2009 Jan 1;115(1):23-35 [19072983.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2328-38 [19332714.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jul;64(2):243-51 [19020877.001]
  • [Cites] Cardiovasc Toxicol. 2009 Jun;9(2):64-9 [19484391.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] J Am Coll Cardiol. 2009 Aug 4;54(6):491-8 [19643307.001]
  • [Cites] Br J Cancer. 2009 Sep 1;101(5):792-802 [19623174.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1249-59 [19776406.001]
  • [Cites] Eur J Cancer. 2009 Nov;45(17):3027-34 [19744853.001]
  • [Cites] BMJ. 2009;339:b4606 [19996459.001]
  • [Cites] Curr Opin Pediatr. 2009 Oct;21(5):585-93 [19584723.001]
  • [Cites] Leukemia. 2010 Feb;24(2):371-82 [20010620.001]
  • [Cites] Leukemia. 2010 Feb;24(2):406-18 [20010621.001]
  • [Cites] Leukemia. 2010 Feb;24(2):265-84 [20010625.001]
  • [Cites] Leukemia. 2010 Feb;24(2):309-19 [20016528.001]
  • [Cites] Leukemia. 2010 Feb;24(2):285-97 [20016531.001]
  • [Cites] Leukemia. 2010 Feb;24(2):255-64 [20016536.001]
  • [Cites] Leukemia. 2010 Feb;24(2):335-44 [20016539.001]
  • [Cites] J Clin Oncol. 2010 Mar 10;28(8):1276-81 [20142585.001]
  • [Cites] J Clin Oncol. 2010 Mar 10;28(8):1308-15 [20142603.001]
  • [Cites] Toxicology. 2010 Apr 11;270(2-3):92-8 [20132857.001]
  • [Cites] J Am Soc Echocardiogr. 2010 May;23(5):465-95; quiz 576-7 [20451803.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Jul;66(2):303-14 [19915844.001]
  • [Cites] JAMA. 2010 Jul 14;304(2):172-9 [20628130.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):2013-22 [20647396.001]
  • [Cites] J Korean Med Sci. 2010 Sep;25(9):1336-42 [20808678.001]
  • [Cites] Physiol Res. 2010;59(5):831-6 [20406046.001]
  • [Cites] J Am Coll Cardiol. 2011 Jan 4;57(1):76-85 [21185505.001]
  • [Cites] JAMA. 2007 Jun 27;297(24):2705-15 [17595271.001]
  • [Cites] Br J Pharmacol. 2007 Jul;151(6):771-8 [17519947.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3179; author reply 3180 [17634500.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4477-89 [17906209.001]
  • [Cites] Pathol Oncol Res. 2007;13(3):249-53 [17922055.001]
  • [Cites] J Pharmacol Exp Ther. 1995 Nov;275(2):1011-8 [7473127.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):328-31 [8636739.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1544-52 [9193351.001]
  • [Cites] Circulation. 1997 Oct 21;96(8):2641-8 [9355905.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):545-50 [9469339.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):818-24 [10071272.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2629-36 [15837978.001]
  • [Cites] Pediatrics. 2005 Jun;115(6):1613-22 [15930224.001]
  • [Cites] J Appl Physiol (1985). 2005 Aug;99(2):445-57 [15557009.001]
  • [Cites] Am Heart J. 2005 Sep;150(3):439-47 [16169321.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):872-3 [16206201.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):561-78 [16351632.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):614-22 [16423847.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Blood. 2007 Feb 1;109(3):896-904 [17003366.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):493-500 [17290056.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Mar;133(3):668-75 [17320563.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2237-43 [10561281.001]
  • [Cites] J Am Coll Cardiol. 2000 Mar 1;35(3):569-82 [10716457.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] Circulation. 2000 Sep 26;102(13):1542-8 [11182983.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3173-81 [11432883.001]
  • [Cites] Circulation. 2001 Jul 17;104(3):310-6 [11457750.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Oct;48(4):297-304 [11710630.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1677-82 [11896119.001]
  • [Cites] Biometrics. 2002 Sep;58(3):621-30 [12229997.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4517-22 [12454107.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1074-81 [12637473.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] Circulation. 2004 Jun 8;109(22):2749-54 [15148277.001]
  • [Cites] N Engl J Med. 2004 Jul 8;351(2):145-53 [15247354.001]
  • [Cites] Pharmacology. 1983;26(4):210-20 [6844396.001]
  • [Cites] Circulation. 1990 Apr;81(4):1161-72 [2138525.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] J Am Coll Cardiol. 1992 Mar 1;19(3):619-29 [1538019.001]
  • [Cites] J Clin Oncol. 1992 May;10(5):810-7 [1569453.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):477-9 [8341214.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):740-7 [8151317.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1738-43 [7760889.001]
  • [Cites] Expert Opin Pharmacother. 2007 Jun;8(8):1039-58 [17516870.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4689-90; author reply 4690-1 [17925567.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4707-13 [17947717.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1106-11 [18309945.001]
  • (PMID = 20850381.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00165087
  • [Grant] United States / NICHD NIH HHS / HD / U01 HD052104; United States / NHLBI NIH HHS / HL / HL078522; United States / NHLBI NIH HHS / HL / HL095127; United States / NHLBI NIH HHS / HL / R01 HL087000; United States / NHLBI NIH HHS / HL / HL094100; United States / NHLBI NIH HHS / HL / F31 HL094100; United States / NICHD NIH HHS / HD / HD052102; United States / NHLBI NIH HHS / HL / HL053392; United States / NHLBI NIH HHS / HL / HL087000; United States / NCI NIH HHS / CA / R01 CA127642; United States / NHLBI NIH HHS / HL / HL079233; United States / NHLBI NIH HHS / HL / HL007188; United States / NHLBI NIH HHS / HL / HL087708; United States / NCI NIH HHS / CA / CA068484; United States / NHLBI NIH HHS / HL / R01 HL095127; United States / NHLBI NIH HHS / HL / R01 HL078522; United States / NIAID NIH HHS / AI / AI50274; United States / NICHD NIH HHS / HD / U01 HD052102; United States / NHLBI NIH HHS / HL / R13 HL087708; United States / NHLBI NIH HHS / HL / K30 HL004537; United States / NHLBI NIH HHS / HL / T32 HL007188; United States / NICHD NIH HHS / HD / HD80002; United States / NIAID NIH HHS / AI / U01 AI050274; United States / NICHD NIH HHS / HD / HD052104; United States / NCI NIH HHS / CA / CA127642; United States / NCI NIH HHS / CA / P01 CA068484; United States / NHLBI NIH HHS / HL / HL072705; United States / NHLBI NIH HHS / HL / R01 HL053392; United States / NHLBI NIH HHS / HL / HL004537; United States / NHLBI NIH HHS / HL / R01 HL072705
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Biomarkers; 0 / Cardiovascular Agents; 0 / Troponin T; 5AR83PR647 / Razoxane; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS483981; NLM/ PMC3756093
  •  go-up   go-down


66. Zibat A, Uhmann A, Nitzki F, Wijgerde M, Frommhold A, Heller T, Armstrong V, Wojnowski L, Quintanilla-Martinez L, Reifenberger J, Schulz-Schaeffer W, Hahn H: Time-point and dosage of gene inactivation determine the tumor spectrum in conditional Ptch knockouts. Carcinogenesis; 2009 Jun;30(6):918-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in Patched (PTCH) have been associated with tumors characteristic both for children [medulloblastoma (MB) and rhabdomyosarcoma (RMS)] and for elderly [basal cell carcinoma (BCC)].
  • Furthermore, they point to key differences in the tumorigenic mechanisms underlying adult and childhood tumors.
  • [MeSH-major] Aging / pathology. Carcinoma, Basal Cell / genetics. Gene Dosage. Gene Silencing. Receptors, Cell Surface / physiology. Rhabdomyosarcoma / genetics


67. Hundsdoerfer P, Dietrich I, Schmelz K, Eckert C, Henze G: XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr Blood Cancer; 2010 Aug;55(2):260-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL.
  • BACKGROUND: Resistance to glucocorticoid induced apoptosis is one of the major risk factors for relapse and poor outcome in childhood acute lymphoblastic leukemia (ALL).
  • PROCEDURE: XIAP protein and mRNA expression were determined in leukemic blasts of 51 childhood ALL patients and normal bone marrow mononuclear cells.
  • RESULTS: XIAP protein but not mRNA expression was found to be highly increased in childhood ALL compared to control bone marrow mononuclear cells (MNC) (median: 3.5 vs. 0.14 ng/10(5) MNC, P < 0.0001) indicating a post-transcriptional regulation of XIAP expression.
  • In patients with T-cell ALL, poor prednisone response was associated with increased XIAP expression (median: 2.8 in good vs. 5.8 in poor responders; P = 0.005).
  • Similarly, T-cell ALL patients suffering adverse events showed higher initial XIAP levels than patients in continuous complete remission (CCR) (median: 2.7 in patients in CCR vs. 5.6 in patients suffering adverse events; P = 0.007).
  • CONCLUSION: In childhood ALL compared to control bone marrow, the expression of the apoptosis inhibitor XIAP is highly increased by post-transcriptional regulation.
  • The association with poor in vivo glucocorticoid response and outcome in T-cell ALL suggests XIAP inhibition as a promising novel approach for the treatment of resistant ALL.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Glucocorticoids / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. X-Linked Inhibitor of Apoptosis Protein / genetics
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Bone Marrow Cells / pathology. Bone Marrow Examination. Child. Drug Resistance. Female. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Male. Monocytes / pathology. Pharmacogenetics. Prognosis. RNA, Messenger / analysis. Treatment Outcome. Up-Regulation


68. Aricò M, Conter V, Valsecchi MG, Rizzari C, Boccalatte MF, Barisone E, Messina C, De Rossi G, Lo Nigro L, Pession A, Locatelli F, Micalizzi C, Basso G: Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study. Haematologica; 2005 Sep;90(9):1186-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study.
  • BACKGROUND AND OBJECTIVES: Treatment of childhood standard-risk (SR) acute lymphoblastic leukemia (ALL) is generally successful.
  • DESIGN AND METHODS: The population of patients with SR ALL included children aged between 1 and 6 years with less than 20,000 WBC/mm3, non-T immunophenotype, DNA index between 1.16 and 1.6, absence of t(9;22) and t(4;11) clonal translocations, no extramedullary leukemia, good response to prednisone and complete remission (CR) at the end of induction therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology


69. Jiménez-Morales S, Miranda-Peralta E, Saldaña-Alvarez Y, Perez-Vera P, Paredes-Aguilera R, Rivera-Luna R, Velázquez-Cruz R, Ramírez-Bello J, Carnevale A, Orozco L: BCR-ABL, ETV6-RUNX1 and E2A-PBX1: prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients. Leuk Res; 2008 Oct;32(10):1518-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BCR-ABL, ETV6-RUNX1 and E2A-PBX1: prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients.
  • This study was conducted to determine the frequency of the most common fusion genes in Mexican pediatric patients with acute lymphoblastic leukemia (ALL).
  • The prevalence of E2A-PBX1 is one of the highest that has been described thus far in childhood ALL.
  • With regards to the immunophenotype, ETV6-RUNX1 was expressed in both pre-B and T-cell cases, while the presence of E2A-PBX1 and BCR-ABL was associated with the pre-B ALL phenotype.
  • The prevalence of E2A-PBX1 in Mexican pediatric cases supports the existence of ethnic differences in the frequency of molecular markers of ALL.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Fusion Proteins, bcr-abl / genetics. Homeodomain Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455790.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / RUNX1 protein, human; 0 / Repressor Proteins; 146150-85-8 / E2A-Pbx1 fusion protein; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


70. Hansson F, Toporski J, Månsson R, Johansson B, Norén-Nyström U, Jacobsen SE, Wiebe T, Larsson M, Sigvardsson M, Castor A: Exit of pediatric pre-B acute lymphoblastic leukaemia cells from the bone marrow to the peripheral blood is not associated with cell maturation or alterations in gene expression. Mol Cancer; 2008;7:67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exit of pediatric pre-B acute lymphoblastic leukaemia cells from the bone marrow to the peripheral blood is not associated with cell maturation or alterations in gene expression.
  • BACKGROUND: Childhood pre-B acute lymphoblastic leukemia (ALL) is a bone marrow (BM) derived disease, which often disseminates out of the BM cavity, where malignant cells to a variable degree can be found circulating in the peripheral blood (PB).
  • In addition, the cell sorting procedure revealed that in 2 out of five investigated patients, a significant fraction of the malignant cells had matured beyond the pre-B cell stage.
  • [MeSH-major] Blood Cells / metabolism. Bone Marrow Cells / metabolism. Gene Expression. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Cell Differentiation. Cell Lineage. Cell Movement. Child. Gene Expression Profiling. Humans. Immunoglobulins / metabolism. In Situ Hybridization, Fluorescence. Stromal Cells / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Genes Dev. 2000 Aug 15;14(16):1983-91 [10950862.001]
  • [Cites] J Clin Invest. 2000 Aug;106(4):511-21 [10953026.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19069-74 [16354839.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2247-56 [11187916.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2267-75 [11187918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):954-8 [12087404.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] J Exp Med. 1996 Dec 1;184(6):2217-29 [8976177.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4150-66 [9834220.001]
  • [Cites] Cell. 2005 Apr 22;121(2):295-306 [15851035.001]
  • [Cites] Nat Med. 2005 Jun;11(6):630-7 [15908956.001]
  • (PMID = 18694513.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501838
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2525657
  •  go-up   go-down


71. Gottardo NG, Hoffmann K, Beesley AH, Freitas JR, Firth MJ, Perera KU, de Klerk NH, Baker DL, Kees UR: Identification of novel molecular prognostic markers for paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol; 2007 May;137(4):319-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel molecular prognostic markers for paediatric T-cell acute lymphoblastic leukaemia.
  • In the last four decades the survival of patients with newly diagnosed childhood T-cell acute lymphoblastic leukaemia (T-ALL) has improved dramatically.
  • [MeSH-major] Gene Expression Profiling. Leukemia-Lymphoma, Adult T-Cell / genetics. Oligonucleotide Array Sequence Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17456054.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA95475
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BTG3 protein, human; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / CFLAR protein, human; 0 / Genetic Markers; 0 / NOTCH2 protein, human; 0 / Proteins; 0 / Receptor, Notch2
  •  go-up   go-down


72. Oliveira Mde F, Brites C, Ferraz N, Magalhaes P, Almeida F, Bittencourt AL: Infective dermatitis associated with the human T cell lymphotropic virus type I in Salvador, Bahia, Brazil. Clin Infect Dis; 2005 Jun 1;40(11):e90-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infective dermatitis associated with the human T cell lymphotropic virus type I in Salvador, Bahia, Brazil.
  • BACKGROUND: Infective dermatitis associated with human T cell lymphotropic virus type I (HTLV-I) infection is a chronic, relapsing eczema of childhood.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15889351.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Haskins K: Pathogenic T-cell clones in autoimmune diabetes: more lessons from the NOD mouse. Adv Immunol; 2005;87:123-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenic T-cell clones in autoimmune diabetes: more lessons from the NOD mouse.
  • T-cell clones that can efficiently transfer diabetes to prediabetic nonobese diabetic (NOD) mice provide a powerful approach to dissecting the autoimmune disease process and for investigating immunoregulation.
  • Diabetogenic T-cell clones carried in culture allow for detailed analysis of T-cell effector function and in vivo activity, and thus the contribution of a single clonotype to pathogenesis can be studied.
  • As T cells comprising most or all of the repertoire in T-cell receptor transgenic (TCR-Tg) mice, diabetogenic T-cell clones have led to new variations on the NOD mouse model of autoimmune disease.
  • T-cell clones are being used to screen peptide libraries and proteomic arrays to identify the autoantigens that drive these clones in vivo and to extend our knowledge of the processes that give rise to these antigens.
  • [MeSH-minor] Animals. Autoantigens. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cell Movement. Chemokines / genetics. Clone Cells / immunology. Cytokines / genetics. Genes, T-Cell Receptor. Humans. Mice. Mice, Inbred NOD. Mice, Transgenic. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Chemokine / genetics. Receptors, Cytokine / genetics

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16102573.001).
  • [ISSN] 0065-2776
  • [Journal-full-title] Advances in immunology
  • [ISO-abbreviation] Adv. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Chemokines; 0 / Cytokines; 0 / RNA, Messenger; 0 / Receptors, Chemokine; 0 / Receptors, Cytokine
  • [Number-of-references] 151
  •  go-up   go-down


74. Morimoto A, Kuriyama K, Hibi S, Todo S, Yoshihara T, Kuroda H, Imashuku S: Prognostic value of early response to treatment combined with conventional risk factors in pediatric acute lymphoblastic leukemia. Int J Hematol; 2005 Apr;81(3):228-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of early response to treatment combined with conventional risk factors in pediatric acute lymphoblastic leukemia.
  • To determine useful prognostic factors in treating childhood acute lymphoblastic leukemia (ALL), we correlated conventional risk factors and bone marrow response 14 days after induction chemotherapy.
  • Our study included 116 precursor B-cell (n = 104) and T-cell (n = 12) ALL patients treated with our protocol between 1988 and 1999.
  • Our new prognostic definition (R1, R2, R3) incorporating day 14 marrow findings is useful to tailor early-phase treatments for better therapeutic results in childhood ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Med Pediatr Oncol. 1986;14(3):191-4 [3528788.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1807-15 [2685179.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1717-26 [9351539.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):729-39 [9722300.001]
  • [Cites] Leuk Lymphoma. 1998 Nov;31(5-6):501-6 [9922040.001]
  • [Cites] Haematologica. 2002 Aug;87(8 Suppl):47-50 [12412390.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2399-402 [12239148.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1238-44 [14607752.001]
  • [Cites] Blood. 2002 Jul 15;100(2):420-6 [12091331.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):275-81 [11167819.001]
  • [Cites] Leukemia. 2001 Mar;15(3):385-90 [11237061.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):389-98 [8636748.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):34-45 [11722407.001]
  • [Cites] Blood. 2000 Feb 1;95(3):790-4 [10648387.001]
  • (PMID = 15902780.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Meleshko AN, Movchan LV, Belevtsev MV, Savitskaja TV: Relative expression of different Ikaros isoforms in childhood acute leukemia. Blood Cells Mol Dis; 2008 Nov-Dec;41(3):278-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative expression of different Ikaros isoforms in childhood acute leukemia.
  • We estimate the relative level of Ikaros mRNA transcripts in 80 childhood ALL cases in comparison with AML and healthy donor groups.
  • We detected eight major isoforms and several minor mutant isoforms in most patients with acute lymphoblastic and myeloid leukemia and in healthy donors, but the relative level of expression varied.
  • We found a negative association between the Ikaros ratio and myeloid coexpression in B-cell ALL, the most prominent was for CD15.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Ikaros Transcription Factor / genetics. Leukemia / genetics
  • [MeSH-minor] Adolescent. Cell Line. Child. Child, Preschool. Gene Expression. Humans. Infant. Infant, Newborn. Mutant Proteins. Protein Isoforms / genetics. Protein Isoforms / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18675565.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mutant Proteins; 0 / Protein Isoforms; 148971-36-2 / Ikaros Transcription Factor
  •  go-up   go-down


76. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W: NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol; 2010 Feb 20;28(6):955-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
  • PURPOSE To conduct a pilot study to determine the safety, feasibility, and engraftment of haploidentical natural killer (NK) cell infusions after an immunosuppressive regimen in children with acute myeloid leukemia (AML).
  • PATIENTS AND METHODS Ten patients (0.7 to 21 years old) who had completed chemotherapy and were in first complete remission of AML were enrolled on the Pilot Study of Haploidentical Natural Killer Cell Transplantation for Acute Myeloid Leukemia (NKAML) study.
  • NK cell chimerism, phenotyping, and functional assays were performed on days 2, 7, 14, 21, and 28 after transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunotherapy. Killer Cells, Natural / transplantation. Leukemia, Myeloid, Acute / therapy. Neoplasm Recurrence, Local / therapy


77. Sadarangani M, Makani J, Komba AN, Ajala-Agbo T, Newton CR, Marsh K, Williams TN: An observational study of children with sickle cell disease in Kilifi, Kenya. Br J Haematol; 2009 Sep;146(6):675-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An observational study of children with sickle cell disease in Kilifi, Kenya.
  • Globally, sickle cell disease (SCD) has its highest prevalence and worst prognosis in sub-Saharan Africa.
  • Children with SCD in Kilifi have a similar degree of anaemia and liver function derangement to patients living in developed countries, but splenomegaly persists into later childhood.
  • [MeSH-major] Anemia, Sickle Cell / physiopathology

  • Genetic Alliance. consumer health - Sickle Cell Disease.
  • MedlinePlus Health Information. consumer health - Sickle Cell Anemia.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Dis Child. 1988 Jun;142(6):589 [3369389.001]
  • [Cites] Blood. 2003 Aug 1;102(3):834-8 [12702514.001]
  • [Cites] East Afr Med J. 1994 Jun;71(6):388-91 [7835262.001]
  • [Cites] Blood Rev. 2004 Mar;18(1):65-73 [14684149.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):83-9 [10631276.001]
  • [Cites] Bull Johns Hopkins Hosp. 1953 Feb;92(2):99-127 [13009339.001]
  • [Cites] Trop Geogr Med. 1992 Jan;44(1-2):37-41 [1496720.001]
  • [Cites] J Trop Pediatr. 1992 Apr;38(2):83-5 [1569641.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1253-7 [16227994.001]
  • [Cites] Pediatr Dent. 2002 Jul-Aug;24(4):321-5 [12212874.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):129-34 [16173973.001]
  • [Cites] J Clin Epidemiol. 1997 Feb;50(2):121-6 [9120504.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Apr;75(4):1994-7 [347452.001]
  • [Cites] J Laryngol Otol. 1987 May;101(5):467-70 [3585161.001]
  • [Cites] Curr Opin Hematol. 2002 Mar;9(2):111-6 [11844993.001]
  • [Cites] Ann Trop Med Parasitol. 1983 Aug;77(4):411-9 [6639186.001]
  • [Cites] Clin Lab Haematol. 1997 Mar;19(1):17-22 [9146942.001]
  • [Cites] Trop Geogr Med. 1979 Dec;31(4):531-5 [542989.001]
  • [Cites] Blood. 1998 Jan 1;91(1):288-94 [9414296.001]
  • [Cites] Ann Trop Med Parasitol. 1979 Aug;73(4):301-10 [315213.001]
  • [Cites] Arch Dis Child. 1992 Jul;67(7):925-9 [1308102.001]
  • [Cites] Am J Hematol. 1993 Mar;42(3):316-21 [8438905.001]
  • [Cites] Br J Haematol. 1981 Aug;48(4):533-43 [7272216.001]
  • [Cites] Blood Rev. 1989 Mar;3(1):18-28 [2650773.001]
  • [Cites] Infect Immun. 2006 Dec;74(12):6700-6 [17000725.001]
  • [Cites] Am J Trop Med Hyg. 2008 Aug;79(2):185-91 [18689622.001]
  • [Cites] Trop Med Int Health. 1997 Jun;2(6):568-71 [9236824.001]
  • [Cites] AMA J Dis Child. 1959 Apr;97(4):418-25 [13636696.001]
  • [Cites] Lancet. 2003 Nov 1;362(9394):1450-5 [14602439.001]
  • [Cites] Clin Pediatr (Phila). 1966 Jul;5(7):403-9 [4223399.001]
  • [Cites] Cent Afr J Med. 1980 Aug;26(8):183-6 [7438202.001]
  • [Cites] Arch Pediatr. 2000 Jan;7(1):16-24 [10668081.001]
  • [Cites] Haematologica. 2005 Apr;90(4):552-4 [15820954.001]
  • [Cites] Acta Haematol. 1999;101(4):178-84 [10436298.001]
  • [Cites] Ann Trop Paediatr. 1988 Jun;8(2):103-7 [2456725.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1996 Nov-Dec;90(6):658-62 [9015508.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1993 Jul-Aug;87(4):386-90 [8249058.001]
  • [Cites] Semin Hematol. 1975 Jul;12(3):267-85 [237323.001]
  • [Cites] Ann Soc Belg Med Trop (1920). 1955 Feb 28;35(1):53-7 [14388457.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1970;64(1):78-93 [5442090.001]
  • [Cites] Dakar Med. 2000;45(1):55-8 [14666792.001]
  • [Cites] Br Med J. 1956 Aug 11;2(4988):333-6 [13342481.001]
  • [Cites] Dig Dis Sci. 1986 Mar;31(3):247-56 [3948629.001]
  • [Cites] Medicine (Baltimore). 1985 Sep;64(5):349-56 [4033412.001]
  • [Cites] Clin Lab Haematol. 2005 Jun;27(3):195-9 [15938726.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6):1604-10 [15585775.001]
  • [Cites] Neurology. 1998 Jul;51(1):169-76 [9674798.001]
  • [Cites] Trop Med Parasitol. 1994 Sep;45(3):219-22 [7899791.001]
  • [Cites] Pediatr Pulmonol. 2004 Sep;38(3):229-32 [15274102.001]
  • [Cites] Nature. 1978 Aug 17;274(5672):701-3 [353566.001]
  • [Cites] Hematol Cell Ther. 1999 Nov;41(5):217-21 [10651122.001]
  • [Cites] Sante Publique. 1997 Mar;9(1):45-60 [9432415.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1656-9 [11425370.001]
  • [Cites] Arch Pediatr. 1998 Sep;5(9):965-9 [9789626.001]
  • [Cites] Br J Haematol. 1987 Feb;65(2):211-5 [3828229.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e500 [17194194.001]
  • [Cites] Niger J Med. 2004 Jan-Mar;13(1):40-3 [15296106.001]
  • [Cites] Postgrad Med J. 2003 Jul;79(933):384-90 [12897216.001]
  • (PMID = 19650883.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 072064; United Kingdom / Wellcome Trust / / 076934; United Kingdom / Wellcome Trust / / 077092
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemoglobins; EC 2.6.1.1 / Aspartate Aminotransferases; RFM9X3LJ49 / Bilirubin
  • [Other-IDs] NLM/ PMC2774158
  •  go-up   go-down


78. Guo Y, Chen YM, Zou Y, Chen XJ, Zhang L, Wang SC, Zhu XF: [Biologic features of 688 cases of childhood acute leukemia-a single centre retrospective study]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Oct;11(10):793-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biologic features of 688 cases of childhood acute leukemia-a single centre retrospective study].
  • OBJECTIVE: To investigate the biologic features of childhood acute leukemia in the northern region of China through a small cohort study in a single center.
  • METHODS: The medical records of 688 children with acute leukemia (age< or =15 years) who were initially diagnosed at Blood Disease Hospital of Chinese Academy of Medical Sciences from October 2003 to June 2006 were retrospectively studied.
  • RESULTS: Four hundred children were diagnosed as acute lymphoblastic leukemia (ALL), with a peak incidence at ages of 1-4 years.
  • Two hundred and eighteen children were classified into B-cell ALL, and 34 into T-cell ALL.
  • E2A-PBX1 fusion gene was expressed in 3.9% of children with B-cell ALL.
  • Two hundred and twenty-two children were diagnosed as acute myeloid leukemia (AML), with a peak incidence at ages of 10-15 years.
  • Acute hybrid leukemia (AHL) was confirmed in 24 children (4.2%), with a median age of 9 years.
  • CONCLUSIONS: There are differences in the biologic features of childhood acute leukemia between the northern region of China and other regions and races, which suggests that there might be differences in the pathogenesis of childhood acute leukemia in different environmental exposures.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19849934.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


79. van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG, Burger NB, Passier M, van Lieshout EM, Kamps WA, Veerman AJ, van Noesel MM, Pieters R: Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia; 2008 Jan;22(1):124-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences.
  • Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is characterized by chromosomal rearrangements possibly enforcing arrest at specific development stages.
  • We studied the relationship between molecular-cytogenetic abnormalities and T-cell development stage to investigate whether arrest at specific stages can explain the prognostic significance of specific abnormalities.
  • We extensively studied 72 pediatric T-ALL cases for genetic abnormalities and expression of transcription factors, NOTCH1 mutations and expression of specific CD markers.
  • Classification into T-cell developmental subgroups was not predictive for outcome.
  • [MeSH-major] Gene Rearrangement / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Neoplasm Recurrence, Local / genetics. Receptor, Notch1 / genetics
  • [MeSH-minor] Basic Helix-Loop-Helix Transcription Factors / genetics. Cell Lineage. Child. Female. Homeodomain Proteins / genetics. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Mutation / genetics. Oncogene Proteins, Fusion / genetics. Prognosis. Proto-Oncogene Proteins / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, gamma-delta / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17928886.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AF10-CALM fusion protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Homeodomain Proteins; 0 / NOTCH1 protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptor, Notch1; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / TLX3 protein, human; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


80. Irving J, Jesson J, Virgo P, Case M, Minto L, Eyre L, Noel N, Johansson U, Macey M, Knotts L, Helliwell M, Davies P, Whitby L, Barnett D, Hancock J, Goulden N, Lawson S, UKALL Flow MRD Group, UK MRD steering Group: Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica; 2009 Jun;94(6):870-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.
  • Minimal residual disease detection, used for clinical management of children with acute lymphoblastic leukemia, can be performed by molecular analysis of antigen-receptor gene rearrangements or by flow cytometric analysis of aberrant immunophenotypes.
  • We report a four color, flow cytometric protocol established and validated by the UK acute lymphoblastic leukemia Flow minimal residual disease group.
  • [MeSH-major] Flow Cytometry / methods. Leukemia, B-Cell / diagnosis. Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Antigens, CD19 / analysis. Antigens, CD34 / analysis. Child. Gene Rearrangement. Humans. Neprilysin / analysis. Polymerase Chain Reaction. Prognosis. Prospective Studies. Receptors, Antigen, T-Cell / genetics. Reference Standards. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Feb 1;95(3):790-4 [10648387.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1939-43 [11069029.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1253-8 [11830473.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1952-8 [11877265.001]
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Acta Haematol. 2004;112(1-2):8-15 [15178999.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1630-6 [15295608.001]
  • [Cites] J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):146-54 [15471219.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] Br J Haematol. 1998 Jul;102(2):553-65 [9695973.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):591-8 [9718378.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1838 [9716617.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3774-81 [9850021.001]
  • [Cites] Leukemia. 2005 Jan;19(1):49-56 [15538405.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122 Suppl:S47-57 [15690642.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):774-82 [15755280.001]
  • [Cites] Cytometry B Clin Cytom. 2005 Nov;68(1):18-24 [16184615.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1109-12 [16885052.001]
  • [Cites] Leukemia. 2007 Apr;21(4):622-6 [17301806.001]
  • [Cites] Cytometry B Clin Cytom. 2008 Nov;74(6):331-40 [18548617.001]
  • [Cites] Blood. 2008 Nov 15;112(10):3982-8 [18780832.001]
  • [CommentIn] Haematologica. 2009 Jun;94(6):748-52 [19483150.001]
  • (PMID = 19377076.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; 0 / Receptors, Antigen, T-Cell; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC2688581
  • [Investigator] Irving J; Jesson J; Virgo P; Case M; Minto L; Eyre L; Noel N; Johansson U; Macey M; Knotts L; Helliwell M; Davies P; Whitby L; Barnett D; Hancock J; Goulden N; Lawson S
  •  go-up   go-down


81. Lindblom A, Heyman M, Gustafsson I, Norbeck O, Kaldensjö T, Vernby A, Henter JI, Tolfvenstam T, Broliden K: Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy. Clin Infect Dis; 2008 Feb 15;46(4):528-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy.
  • We evaluated the complications of parvovirus B19 infection, including delays in the scheduled course of chemotherapy, in children with acute lymphoblastic leukemia (ALL).
  • Clinical and laboratory data were collected from the Nordic Childhood Leukemia Registry and from medical records.
  • Screening for parvovirus B19 DNA by quantitative polymerase chain reaction in pediatric patients with ALL and unexplained cytopenia is suggested.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Pancytopenia / virology. Parvoviridae Infections / diagnosis. Parvoviridae Infections / pathology. Parvovirus B19, Human / isolation & purification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Infect Dis. 2008 Feb 15;46(4):537-9 [18194096.001]
  • (PMID = 18194100.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Viral
  •  go-up   go-down


82. Atan Ö, Aksu G, Özgenç F, Akman SA, Karaca NE, Sertoz R, Yağci RV, Kütükçüler N: Determination of intracellular Th1/Th2 type cytokines in lymphocytes of chronic hepatitis B patients treated with interferon-alpha. Turk J Gastroenterol; 2010 Dec;21(4):401-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Host-related immune factors in childhood chronic hepatitis B and change in the initial profile with interferon (IFN)-α treatment need to be clarified.
  • Pre- and post-treatment percentages of interleukin (IL)-2 and IFN-γ in CD4+ T cells were assessed to determine intracellular T helper cell 1 (Th1) type cytokine expression.
  • Similarly, percentages of intracellular IL-2 and IFN-γ were detected to verify cytotoxic T cell 1 (Tc1) type cytokine expression in CD8+ T cells.

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21331994.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Cytokines; 0 / IL2 protein, human; 0 / IL4 protein, human; 0 / Interferon-alpha; 0 / Interleukin-13; 0 / Interleukin-2; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


83. Fischer S, Mann G, Konrad M, Metzler M, Ebetsberger G, Jones N, Nadel B, Bodamer O, Haas OA, Schmitt K, Panzer-Grümayer ER: Screening for leukemia- and clone-specific markers at birth in children with T-cell precursor ALL suggests a predominantly postnatal origin. Blood; 2007 Oct 15;110(8):3036-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for leukemia- and clone-specific markers at birth in children with T-cell precursor ALL suggests a predominantly postnatal origin.
  • Childhood T-cell precursor acute lymphoblastic leukemia (TCP ALL) is an aggressive disease with a presumably short latency that differs in many biologic respects from B-cell precursor (BCP) ALL.
  • We therefore addressed the issue of in utero origin of this particular type of leukemia by tracing oncogenic mutations and clone-specific molecular markers back to birth.
  • These markers included various first- and second-hit genetic alterations (TCRD-LMO2 breakpoint regions, n = 2; TAL1 deletions, n = 3; Notch1 mutations, n = 1) and nononcogenic T-cell receptor rearrangements (n = 13) that were derived from leukemias of 16 children who were 1.5 to 11.2 years old at diagnosis of leukemia.
  • Despite highly sensitive polymerase chain reaction (PCR) approaches (1 cell with a specific marker among 100,000 normal cells), we identified the leukemic clone in the neonatal blood spots in only 1 young child.
  • [MeSH-major] Biomarkers, Tumor / genetics. Gene Rearrangement, T-Lymphocyte / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17557895.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Proto-Oncogene Proteins; 0 / Receptor, Notch1; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


84. Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML: Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res; 2009 Mar;33(3):355-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.
  • Juvenile myelomonocytic leukemia (JMML) is an aggressive childhood myeloproliferative disorder characterized by the overproduction of myelomonocytic cells.

  • Genetic Alliance. consumer health - Juvenile Myelomonocytic Leukemia (JMML).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2006 Mar;38(3):294-6 [16474404.001]
  • [Cites] Nat Genet. 2005 Oct;37(10):1038-40 [16170316.001]
  • [Cites] Science. 2006 Mar 3;311(5765):1287-90 [16439621.001]
  • [Cites] Am J Hum Genet. 2006 Jul;79(1):129-35 [16773572.001]
  • [Cites] J Cell Biol. 2006 Oct 9;175(1):87-97 [17015617.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):75-9 [17143282.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):70-4 [17143285.001]
  • [Cites] Leukemia. 2007 Mar;21(3):556-60 [17268527.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5477-80 [17332249.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):1013-7 [17603482.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):1007-12 [17603483.001]
  • [Cites] Pediatr Blood Cancer. 2007 Oct 15;49(5):629-33 [16991133.001]
  • [Cites] Blood. 2008 Jan 15;111(2):966-7; author reply 967-8 [18182584.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1124-7 [18000165.001]
  • [Cites] Br J Haematol. 2008 Mar;140(6):610-24 [18302710.001]
  • [Cites] Br J Haematol. 2008 May;141(5):567-75 [18422786.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):335-43 [18835035.001]
  • [Cites] Pediatr Res. 2009 Mar;65(3):334-40 [19047918.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3631-52 [10550163.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 Nov-Dec;21(6):523-7 [10598665.001]
  • [Cites] Blood. 2000 Jan 15;95(2):639-45 [10627474.001]
  • [Cites] Mol Cell. 2000 Jan;5(1):189-95 [10678181.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):465-8 [11704759.001]
  • [Cites] Leukemia. 2002 Apr;16(4):645-9 [11960345.001]
  • [Cites] Am J Hum Genet. 2002 Jun;70(6):1555-63 [11992261.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4147-53 [12010819.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):148-50 [12717436.001]
  • [Cites] J Med Genet. 2003 Sep;40(9):704-8 [12960218.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602 [14699048.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2325-31 [14644997.001]
  • [Cites] Curr Hematol Rep. 2004 May;3(3):203-9 [15087069.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4243-50 [14982883.001]
  • [Cites] Blood. 1974 Mar;43(3):341-50 [4521369.001]
  • [Cites] J Pediatr. 1978 Jun;92(6):925-9 [96239.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6456-61 [3465439.001]
  • [Cites] Blood. 1991 Mar 1;77(5):925-9 [1704804.001]
  • [Cites] Br J Haematol. 1992 Jan;80(1):40-8 [1311195.001]
  • [Cites] Blood. 1992 Mar 1;79(5):1311-8 [1536955.001]
  • [Cites] Cell. 1992 Apr 17;69(2):265-73 [1568246.001]
  • [Cites] Nature. 1992 Apr 23;356(6371):713-5 [1570015.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):597-601 [8302341.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):637-9 [8302348.001]
  • [Cites] Blood. 1994 Nov 15;84(10):3435-9 [7949098.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):137-43 [8563750.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):144-8 [8563751.001]
  • [Cites] Development. 1996 Apr;122(4):1137-46 [8620840.001]
  • [Cites] N Engl J Med. 1997 Jun 12;336(24):1713-20 [9180088.001]
  • [Cites] J Pediatr. 1997 Jun;130(6):885-9 [9202609.001]
  • [Cites] Leuk Res. 1997 Aug;21(8):697-701 [9379676.001]
  • [Cites] J Med Genet. 2004 Nov;41(11):e117 [15520399.001]
  • [Cites] Blood. 2005 Jan 1;105(1):410-9 [15353481.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):179-91 [15710330.001]
  • [Cites] Blood. 2005 Jul 1;106(1):311-7 [15761018.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2183-5 [15928039.001]
  • [Cites] Nat Genet. 2006 Mar;38(3):331-6 [16474405.001]
  • (PMID = 18954903.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5K22CA113577-03; United States / NCI NIH HHS / CA / K22 CA113557-03; United States / NCI NIH HHS / CA / R13 CA132568; United States / NCI NIH HHS / CA / R13 CA132568-02; United States / NCI NIH HHS / CA / CA132568-02; United States / NCI NIH HHS / CA / K22 CA113557; United States / NHLBI NIH HHS / HL / R01 HL082981; United States / NCI NIH HHS / CA / CA113557-03; United States / NHLBI NIH HHS / HL / 5R01HL082981-03; United States / NCI NIH HHS / CA / 3R13CA132568-02
  • [Publication-type] Congresses; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurofibromin 1; EC 3.1.3.48 / PTPN11 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS95430; NLM/ PMC2692866
  •  go-up   go-down


85. Bien E, Stachowicz-Stencel T, Szalewska M, Krawczyk M, Synakiewicz A, Dubaniewicz-Wybieralska M, Zielinski P, Adamkiewicz-Drozynska E, Balcerska A: Poor-risk high-grade gliomas in three survivors of childhood acute lymphoblastic leukaemia--an overview of causative factors and possible therapeutic options. Childs Nerv Syst; 2009 May;25(5):619-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor-risk high-grade gliomas in three survivors of childhood acute lymphoblastic leukaemia--an overview of causative factors and possible therapeutic options.
  • PURPOSE: Malignant high-grade gliomas are the most common secondary neoplasms in children cured of acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Cranial Irradiation / adverse effects. Glioma / etiology. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Supratentorial Neoplasms / etiology. Supratentorial Neoplasms / therapy. Survivors

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2009 Jul;25(7):779; author reply 781-2 [19452153.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3858-64 [16921038.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2701-7 [15226337.001]
  • [Cites] J Pediatr. 1991 Dec;119(6):985-9 [1960624.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(2):257-68 [17981026.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 May;26(5):1263-9 [15891195.001]
  • [Cites] J Clin Invest. 1992 Feb;89(2):640-7 [1737852.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4237-9 [7671227.001]
  • [Cites] Strahlenther Onkol. 2005 Jun;181(6):372-7 [15925979.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2497-502 [7595699.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7936-41 [16258093.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2257-66 [11187917.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:142-6 [17124053.001]
  • [Cites] Curr Opin Hematol. 2003 Jul;10(4):290-6 [12799535.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1798-809 [12721257.001]
  • [Cites] JAMA. 2007 Mar 21;297(11):1207-15 [17374815.001]
  • [Cites] Childs Nerv Syst. 2008 Jul;24(7):793-805 [18392837.001]
  • [Cites] Haematologica. 2003 May;88(5):555-60 [12745275.001]
  • [Cites] Childs Nerv Syst. 2007 Feb;23(2):185-93 [17021727.001]
  • [Cites] Blood. 2000 May 1;95(9):2770-5 [10779419.001]
  • [Cites] Neurol India. 2004 Sep;52(3):375-7 [15472432.001]
  • [Cites] Cancer. 2008 May 15;112(10 ):2267-73 [18327820.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):817-24 [15305415.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):451-6 [7960210.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jan;42(1):24-9 [14752790.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):263-5 [9167750.001]
  • [Cites] Blood Cells Mol Dis. 2003 Jul-Aug;31(1):84-92 [12850490.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4257-64 [12036851.001]
  • (PMID = 19301014.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 30
  •  go-up   go-down


86. Bell W, Warner JT, Evans WD, Webb DK, Mullen RH, Gregory JW: Perception of effort at low and moderate intensity exercise in survivors of childhood acute lymphoblastic leukaemia. Ann Hum Biol; 2006 May-Jun;33(3):357-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perception of effort at low and moderate intensity exercise in survivors of childhood acute lymphoblastic leukaemia.
  • OBJECTIVE: The study examined the degree to which male and female survivors of acute lymphoblastic leukaemia (ALL) perceive effort at low and moderate intensity exercise in association with related physiological variables.
  • [MeSH-major] Physical Exertion / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17092872.001).
  • [ISSN] 0301-4460
  • [Journal-full-title] Annals of human biology
  • [ISO-abbreviation] Ann. Hum. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


87. Hahn YS, Kim JG: Pathogenesis and clinical manifestations of juvenile rheumatoid arthritis. Korean J Pediatr; 2010 Nov;53(11):921-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Juvenile rheumatoid arthritis (JRA) is the most common rheumatic childhood disease; its onset is before 16 years of age and it persists for at least 6 weeks.
  • The first 2 types of JRA are regarded as T helper 1 (Th1) cell-mediated inflammatory disorders, mainly based on the abundance of activated Th1 cells in the inflamed synovium and the pathogenetic role of proinflammatory cytokines that are mainly produced by Th1 cell-stimulated monocytes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 1995 Feb;38(2):211-20 [7848311.001]
  • [Cites] J Rheumatol. 1995 Nov;22(11):2020-6 [8596138.001]
  • [Cites] Arthritis Rheum. 1996 May;39(5):797-809 [8639177.001]
  • [Cites] Arthritis Rheum. 1996 May;39(5):829-35 [8639180.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4824-30 [8639855.001]
  • [Cites] Arthritis Rheum. 1996 Oct;39(10):1703-10 [8843861.001]
  • [Cites] Acta Paediatr Jpn. 1997 Apr;39(2):242-4 [9141265.001]
  • [Cites] J Rheumatol. 1997 Jul;24(7):1403-9 [9228145.001]
  • [Cites] Arch Dis Child. 1997 Dec;77(6):530-4 [9496193.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3513-21 [9531313.001]
  • [Cites] Int Rev Immunol. 1998;16(5-6):541-51 [9646176.001]
  • [Cites] J Immunol. 1998 Jul 1;161(1):409-14 [9647250.001]
  • [Cites] Clin Rheumatol. 1998;17(4):288-92 [9776110.001]
  • [Cites] Arthritis Rheum. 1991 Sep;34(9):1158-63 [1930333.001]
  • [Cites] Ann Rheum Dis. 1990 Aug;49(8):620-3 [2396868.001]
  • [Cites] Arthritis Rheum. 1977 Mar;20(2 Suppl):195-9 [318120.001]
  • [Cites] J Pediatr. 1974 Sep;85(3):313-7 [4431493.001]
  • [Cites] J Pediatr. 1970 Aug;77(2):203-10 [5431202.001]
  • [Cites] N Engl J Med. 1955 Dec 22;253(25):1107-10 [13272847.001]
  • [Cites] Clin Exp Rheumatol. 2003 Sep-Oct;21(5):650-6 [14611119.001]
  • [Cites] Lancet. 2007 Mar 3;369(9563):767-78 [17336654.001]
  • [Cites] J Rheumatol. 2007 May;34(5):1133-8 [17343315.001]
  • [Cites] Nat Clin Pract Rheumatol. 2006 Nov;2(11):619-26 [17075601.001]
  • [Cites] Arthritis Rheum. 2006 Nov;54(11):3551-63 [17075861.001]
  • [Cites] J Exp Med. 2006 Nov 27;203(12):2673-82 [17088434.001]
  • [Cites] Ann Rheum Dis. 2007 May;66(5):589-98 [17170049.001]
  • [Cites] EMBO J. 1991 Dec;10(13):4025-31 [1721867.001]
  • [Cites] Nat Med. 2007 Apr;13(4):423-31 [17384649.001]
  • [Cites] Arthritis Rheum. 2007 Jun;56(6):1974-84 [17530723.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Nov;83(22):8749-53 [3490671.001]
  • [Cites] J Pediatr. 1985 Feb;106(2):254-5 [3968615.001]
  • [Cites] J Clin Invest. 1994 May;93(5):2114-9 [8182142.001]
  • [Cites] J Immunol. 1993 Dec 1;151(11):6602-7 [8245488.001]
  • [Cites] Clin Exp Immunol. 1993 Oct;94(1):145-9 [8403497.001]
  • [Cites] Arthritis Rheum. 1997 Nov;40(11):1962-6 [9365084.001]
  • [Cites] J Rheumatol. 1998 Oct;25(10):1991-4 [9779856.001]
  • [Cites] Cytokine. 2000 Jul;12(7):1092-9 [10880256.001]
  • [Cites] Arthritis Rheum. 2000 Aug;43(8):1858-65 [10943877.001]
  • [Cites] J Rheumatol. 2002 Jul;29(7):1520-30 [12136914.001]
  • [Cites] Scand J Rheumatol. 2002;31(3):123-8 [12195624.001]
  • [Cites] Arthritis Res. 2002;4(5):302-6 [12223104.001]
  • [Cites] Arthritis Rheum. 2002 Sep;46(9):2539-41; author reply 2541-2 [12355506.001]
  • [Cites] Rheum Dis Clin North Am. 2002 Aug;28(3):503-30 [12380368.001]
  • [Cites] J Rheumatol. 2003 Feb;30(2):394-400 [12563701.001]
  • [Cites] J Rheumatol. 2003 Feb;30(2):401-3 [12563702.001]
  • [Cites] Rheumatology (Oxford). 2003 Feb;42(2):375-9 [12595640.001]
  • [Cites] Trends Immunol. 2003 Apr;24(4):155-8 [12697438.001]
  • [Cites] J Clin Invest. 1999 May;103(9):1345-52 [10225978.001]
  • [Cites] Arthritis Rheum. 1999 Jun;42(6):1101-8 [10366102.001]
  • [Cites] Arthritis Rheum. 1999 Nov;42(11):2261-8 [10555018.001]
  • [Cites] Arthritis Rheum. 2000 Apr;43(4):765-74 [10765921.001]
  • [Cites] Nat Genet. 2001 Jan;27(1):20-1 [11137993.001]
  • [Cites] Arthritis Rheum. 2001 Apr;44(4):794-801 [11315918.001]
  • [Cites] Arthritis Rheum. 2001 Jul;44(7):1716-7 [11465725.001]
  • [Cites] Arthritis Rheum. 2001 Sep;44(9):2176-84 [11592383.001]
  • [Cites] Arch Dis Child. 2001 Nov;85(5):421-6 [11668110.001]
  • [Cites] Clin Rheumatol. 2002 Feb;21(1):52-6 [11954886.001]
  • [Cites] Clin Exp Rheumatol. 2002 Mar-Apr;20(2):121-3 [12051388.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1057-61 [12522256.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1033-6 [12532024.001]
  • [Cites] Arch Dis Child. 2003 Mar;88(3):186-91 [12598373.001]
  • [Cites] Arthritis Rheum. 2003 Sep;48(9):2622-6 [13130482.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9784-8 [1409699.001]
  • [Cites] J Immunol. 2003 Dec 1;171(11):6173-7 [14634133.001]
  • [Cites] Int J Cardiol. 1992 Jan;34(1):57-62 [1548110.001]
  • [Cites] Arthritis Res Ther. 2005;7(2):R256-67 [15743472.001]
  • [Cites] Arthritis Rheum. 2005 Mar;52(3):818-25 [15751095.001]
  • [Cites] J Exp Med. 2005 May 2;201(9):1479-86 [15851489.001]
  • [Cites] Arthritis Rheum. 2005 Jun;52(6):1694-9 [15934099.001]
  • [Cites] J Rheumatol Suppl. 1992 Apr;33:70-4 [1593606.001]
  • [Cites] J Exp Med. 2005 Jun 6;201(11):1793-803 [15939793.001]
  • [Cites] Biochem J. 1990 Feb 1;265(3):621-36 [1689567.001]
  • [Cites] Spine J. 2002 Mar-Apr;2(2):89-94 [14588266.001]
  • [Cites] Arthritis Rheum. 2004 Feb;50(2):650-9 [14872510.001]
  • [Cites] Arthritis Rheum. 2004 Apr;50(4):1286-95 [15077313.001]
  • [Cites] J Immunol. 2004 May 15;172(10):6435-43 [15128835.001]
  • [Cites] Rheumatology (Oxford). 2004 Sep;43(9):1091-6 [15199218.001]
  • [Cites] Curr Opin Rheumatol. 2004 Sep;16(5):588-94 [15314499.001]
  • [Cites] Arthritis Rheum. 2004 Dec;50(12):3762-71 [15593206.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2955-62 [15598812.001]
  • [Cites] Arthritis Res Ther. 2005;7(1):R30-7 [15642140.001]
  • [Cites] Exp Dermatol. 2005 Apr;14(4):259-65 [15810883.001]
  • [Cites] Curr Opin Rheumatol. 2005 Sep;17(5):612-6 [16093841.001]
  • [Cites] Immunity. 2006 Jun;24(6):677-88 [16782025.001]
  • [Cites] Curr Opin Rheumatol. 2006 Sep;18(5):482-9 [16896287.001]
  • [Cites] Ann Rheum Dis. 1995 Oct;54(10):836-40 [7492224.001]
  • (PMID = 21218013.001).
  • [ISSN] 2092-7258
  • [Journal-full-title] Korean journal of pediatrics
  • [ISO-abbreviation] Korean J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3012271
  • [Keywords] NOTNLM ; Child / Cytokines / Inflammation / Juvenile arthritis
  •  go-up   go-down


88. Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ, Stubbs A, Cools J, Nagata K, Fornerod M, Buijs-Gladdines J, Horstmann M, van Wering ER, Soulier J, Pieters R, Meijerink JP: The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood; 2008 May 1;111(9):4668-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia.
  • T-cell acute lymphoblastic leukemia (T-ALL) is mostly characterized by specific chromosomal abnormalities, some occurring in a mutually exclusive manner that possibly delineate specific T-ALL subgroups.
  • This deletion results in a conserved SET-NUP214 fusion product, which was also identified in the T-ALL cell line LOUCY.
  • We conclude that SET-NUP214 may contribute to the pathogenesis of T-ALL by enforcing T-cell differentiation arrest.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4445-54 [17855633.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Mol Cell Biol. 1990 Aug;10(8):4016-26 [2370860.001]
  • [Cites] Cancer Genet Cytogenet. 1990 Oct 15;49(2):241-8 [2208060.001]
  • [Cites] Stat Med. 1990 Jul;9(7):811-8 [2218183.001]
  • [Cites] Mol Cell Biol. 1992 Apr;12(4):1687-97 [1549122.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Oct;5(3):227-34 [1384675.001]
  • [Cites] Oncogene. 1996 Oct 17;13(8):1801-8 [8895527.001]
  • [Cites] Mol Cell Biol. 1997 Jan;17(1):495-505 [8972230.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3145-57 [9214632.001]
  • [Cites] EMBO J. 1998 Jul 1;17(13):3714-25 [9649441.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17765-70 [15591353.001]
  • [Cites] FEBS Lett. 2005 Jan 31;579(3):757-62 [15670842.001]
  • [Cites] Leukemia. 2005 Mar;19(3):358-66 [15674412.001]
  • [Cites] Cell. 2005 Apr 22;121(2):167-78 [15851025.001]
  • [Cites] Blood. 2005 Jul 1;106(1):274-86 [15774621.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1116-27 [16079112.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Leukemia. 2005 Nov;19(11):1948-57 [16107895.001]
  • [Cites] Leukemia. 2006 Jan;20(1):82-6 [16270038.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Genes Dev. 2006 May 1;20(9):1123-36 [16618801.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1496-510 [16826225.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1017-24 [16921363.001]
  • [Cites] Haematologica. 2006 Sep;91(9):1212-21 [16956820.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8022-31 [16954387.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3520-9 [16873670.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Leukemia. 2007 Jan;21(1):121-8 [17039236.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Bioinformatics. 2002;18 Suppl 1:S96-104 [12169536.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1157-63 [12764384.001]
  • [Cites] Cell. 2001 Jan 12;104(1):119-30 [11163245.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1197-204 [11830466.001]
  • [Cites] Blood. 2003 Jul 1;102(1):262-8 [12637319.001]
  • [Cites] Leukemia. 2004 Feb;18(2):337-40 [14671643.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(6):2373-84 [14993277.001]
  • [Cites] Haematologica. 2007 Feb;92(2):232-5 [17296573.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Nat Genet. 2007 May;39(5):593-5 [17435759.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):654-66 [17569777.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1251-61 [17452517.001]
  • [Cites] J Cell Physiol. 2008 Feb;214(2):322-33 [17620317.001]
  • [Cites] Int J Cancer. 2004 Sep 10;111(4):501-7 [15239126.001]
  • (PMID = 18299449.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA11560
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / Histone Chaperones; 0 / Homeodomain Proteins; 0 / NUP214 protein, human; 0 / Nuclear Pore Complex Proteins; 0 / Oncogene Proteins, Fusion; 0 / SET protein, human; 0 / Transcription Factors; 157907-48-7 / HoxA protein
  • [Other-IDs] NLM/ PMC2343598
  •  go-up   go-down


89. Athanassiadou F, Tragiannidis A, Rousso I, Katsos G, Sidi V, Papageorgiou T, Papastergiou C, Tsituridis I, Koliouskas D: Bone mineral density in survivors of childhood acute lymphoblastic leukemia. Turk J Pediatr; 2006 Apr-Jun;48(2):101-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone mineral density in survivors of childhood acute lymphoblastic leukemia.
  • The aim of our study was to evaluate bone metabolism with measurement of bone mineral density (BMD) after management (chemo-, radiotherapy) for childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bone Diseases, Metabolic / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


90. Heide R, Zuidema E, Beishuizen A, Den Hollander JC, Van Gysel D, Seyger MM, Pasmans SG, Kakourou T, Oranje AP: Clinical aspects of diffuse cutaneous mastocytosis in children: two variants. Dermatology; 2009;219(4):309-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results of laboratory testing including mast cell mediator levels, and clinical symptoms on presentation and during follow-up were analyzed.
  • RESULTS: The levels of relevant mast cell mediators were initially high in all cases but declined sharply later on.
  • CONCLUSIONS: DCM is a rare variant of cutaneous childhood onset mastocytosis.
  • It appears to follow a course similar to that in other types of childhood onset mastocytosis, taking into account the decreased symptoms and the levels of mast cell mediators during follow-up.
  • Obtaining a bone marrow biopsy should be considered only in those cases where there is no improvement or even worsening of signs or symptoms and persistent elevated levels of mast cell mediators.

  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Cutaneous mastocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19797893.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


91. Sazawal S, Bakhshi S, Raina V, Swaroop C, Saxena R: Detection and clinical relevance of BCR-ABL fusion gene in childhood T-lineage acute lymphoblastic leukemia: a report on 4 cases. J Pediatr Hematol Oncol; 2009 Nov;31(11):850-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and clinical relevance of BCR-ABL fusion gene in childhood T-lineage acute lymphoblastic leukemia: a report on 4 cases.
  • The bcr-abl rearrangement has rarely been reported in T-lineage acute lymphoblastic leukemia and the clinical significance of this translocation is currently unknown.
  • We screened 28 children with T-lineage acute lymphoblastic leukemia at diagnosis by reverse transcription polymerase chain reaction for major and minor break point regions of bcr-abl fusion gene.
  • [MeSH-major] Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 9 / genetics. Genes, abl / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic


92. Kamps WA, van der Pal-de Bruin KM, Veerman AJ, Fiocco M, Bierings M, Pieters R: Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia; 2010 Feb;24(2):309-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004.
  • The Dutch Childhood Oncology Group (DCOG) has used two treatment strategies for children with acute lymphoblastic leukemia (ALL) based on Pinkel's St Jude Total Therapy or the Berlin-Frankfurt-Münster (BFM) backbone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


93. Zhang YT, Luo ZF, Fang JP, Guo HX, Huang K, Li CK: [Detection of minimal residual disease in childhood acute lymphoblastic leukemia by using real-time quantitative PCR]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1235-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of minimal residual disease in childhood acute lymphoblastic leukemia by using real-time quantitative PCR].
  • This study was purposed to detect the minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) by using real time quantitative PCR (RQ-PCR) .
  • It is concluded that Ig/TCR gene rearrangements can be used as a marker to detect MRD in childhood ALL; the technique of QR-PCR with SYBR green dye staining is reliable, relatively sensitive and easy performable method which can be used in routine detection for childhood ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129267.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


94. Wolf E, Harms H, Winkler J, Reulbach U, Kirchner T, Niedobitek G, Baumann I: Terminal deoxynucleotidyl transferase-positive cells in trephine biopsies following bone marrow or peripheral stem cell transplantation reflect vigorous B-cell generation. Histopathology; 2005 Apr;46(4):442-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Terminal deoxynucleotidyl transferase-positive cells in trephine biopsies following bone marrow or peripheral stem cell transplantation reflect vigorous B-cell generation.
  • AIMS: Bone marrow is the major site of B-cell generation in humans.
  • While in early childhood a high number of B-cell precursors is found in the bone marrow, only very few such cells are usually detectable in adult bone marrow.
  • To assess the number of immature B cells present after haematopoietic cell transplantation the number of terminal deoxynucleotidyl transferase (TdT)-positive cells in regenerating bone marrow of adult patients was analysed.
  • METHODS AND RESULTS: Bone marrow biopsy specimens were analysed from patients after allogeneic bone marrow transplantation (BMT; n = 14) or stem cell transplantation (SCT; n = 25) and autologous BMT (n = 9).
  • Immunoreactivity for CD79a, CD20 and CD10 was used to confirm their B-cell origin.
  • We found a significant increase in the numbers of B-cell precursors in the bone marrow after allogeneic and autologous BMT/SCT compared with adult controls (P = 0.022).
  • To analyse this in detail, we followed some patients after allogeneic BMT/SCT for up to 1445 days, when a marked B-cell increase was still detectable.
  • CONCLUSIONS: Bone marrow of adult patients after BMT/SCT is capable of initiating vigorous precursor B-cell generation, which is not seen in untransplanted adults.
  • Only in two young adult patients did it reach the magnitude of B-cell generation seen in infantile bone marrow where immunocompetent B cells are produced normally.
  • A marked increase in number of immature B cells post-transplant may mimic B-cell acute lymphoblastic leukaemia (B-ALL).
  • Since reactive and neoplastic B-cell precursors share the same immunophenotype in paraffin-embedded tissue, additional tools, particularly molecular techniques, may have to be employed to establish the correct diagnosis.
  • [MeSH-major] B-Lymphocytes / cytology. Bone Marrow Transplantation. DNA Nucleotidylexotransferase / blood. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Biopsy. Bone Marrow / pathology. Child. Child, Preschool. Humans. Infant. Leukemia / pathology. Leukemia / therapy. Lymphocyte Count. Lymphoma / pathology. Lymphoma / therapy. Lymphopoiesis. Middle Aged. Myelodysplastic Syndromes / pathology. Myelodysplastic Syndromes / therapy. Time Factors. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15810956.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.7.31 / DNA Nucleotidylexotransferase
  •  go-up   go-down


95. Petridou E, Mantzoros CS, Dessypris N, Dikalioti SK, Trichopoulos D: Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer; 2006 Jan 16;94(1):156-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adiponectin in relation to childhood myeloblastic leukaemia.
  • Adiponectin, an adipocyte-specific secretory protein known to induce apoptosis, has been reported to be inversely related to breast and endometrial cancers and recently found to inhibit proliferation of myeloid but not lymphoid cell lines.
  • We hypothesised that adiponectin may be inversely associated with acute myeloblastic leukaemia (AML), but not with acute lymphoblastic leukaemia of B (ALL-B) or T (ALL-T) cell origin in children.
  • Blood samples and clinical information were collected over the period 1996-2000 from 201 children (0-14 years old) with leukaemia (22 AML, 161 ALL-B and 18 ALL-T cases) through a national network of childhood Hematology-Oncology units in Greece and from 201 controls hospitalised for minor pediatric ailments.
  • Biological plausibility and empirical evidence point to the importance of this hormone in the pathogenesis of childhood AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / physiopathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Adiponectin / analysis. Adiponectin / biosynthesis. Adolescent. Apoptosis. Body Height. Body Weight. Case-Control Studies. Cell Proliferation. Child. Child, Preschool. Female. Gene Expression Profiling. Greece. Humans. Infant. Infant, Newborn. Leukemia, B-Cell. Leukemia, T-Cell. Male. Odds Ratio

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2004 Nov;127(3):243-63 [15491284.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1160-3 [15001602.001]
  • [Cites] BMJ. 1993 Sep 25;307(6907):774 [8219951.001]
  • [Cites] Nature. 1996 Jul 25;382(6589):352-3 [8684463.001]
  • [Cites] Cancer Causes Control. 1996 Sep;7(5):553-9 [8877054.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83 [10092513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5728-33 [10318952.001]
  • [Cites] Clin Lab Sci. 2004 Fall;17(4):235-45 [15559730.001]
  • [Cites] Eur J Endocrinol. 2004 Dec;151(6):741-6 [15588241.001]
  • [Cites] Am J Epidemiol. 2005 Jan 1;161(1):27-32 [15615910.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1154-7 [16077074.001]
  • [Cites] Circulation. 1999 Dec 21-28;100(25):2473-6 [10604883.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1723-32 [10961870.001]
  • [Cites] Cancer Causes Control. 2000 Sep;11(8):765-71 [11065014.001]
  • [Cites] Circulation. 2001 Feb 27;103(8):1057-63 [11222466.001]
  • [Cites] Diabetes. 2002 Jun;51(6):1884-8 [12031977.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5662-7 [12466369.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):993-7 [12629074.001]
  • [Cites] Diabetologia. 2003 Apr;46(4):459-69 [12687327.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4823-31 [14557461.001]
  • [Cites] Am J Epidemiol. 2003 Oct 15;158(8):724-35 [14561661.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5699-704 [14654554.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81 [14983034.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1102-7 [15001594.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 20;96(20):1549-56 [15494605.001]
  • (PMID = 16404369.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ADIPOQ protein, human; 0 / Adiponectin
  • [Other-IDs] NLM/ PMC2361080
  •  go-up   go-down


96. Tsurusawa M, Taga T, Horikoshi Y, Ogawa A, Kikuta A, Kanegane H, Matsushita T, Hyakuna N, Shimomura Y, Ohshima K, Lymphoma Committee of Japanese Childhood Cancer and Leukemia: Favourable outcomes in children with diffuse large B-cell lymphoma treated by a short-term ALL-like regimen: a report on the NHL960 study from the Japanese Childhood Cancer and Leukemia Study Group. Leuk Lymphoma; 2008 Apr;49(4):734-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favourable outcomes in children with diffuse large B-cell lymphoma treated by a short-term ALL-like regimen: a report on the NHL960 study from the Japanese